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ABSTRACT 
The anti-inflammatory and insulin sensitizing attributes of high circulating 
adiponectin concentrations in the mouse were recently suggested to occur as a result of 
subcutaneous adipose tissue expansion.  Although there is a plethora of data describing 
the affects adiponectin has on metabolism and inflammation, there are limited data on its 
role in the growth of adipose tissue.  Our data in adiponectin null mice indicate, the 
consumption of a high fat diet does not significantly change body composition from that 
of diet matched wild type mice. Furthermore, there was no observable difference in the 
inflammatory profile of our adiponectin null mice fed high fat diet.  
In the absence of the expected increase in adipose tissue, we sought to identify the 
role of adiponectin in the proliferation and differentiation of stromal vascular cells 
obtained from ob/ob obese mice or wild type controls. Our study identified a significant 
reduction in the differentiation of cells derived from ob/ob animals when treated with 
adiponectin. Conversely, there was no observable change in differentiation of the wild 
type cells with treatment of adiponectin, leptin or the combination of the two. 
Furthermore, we report a significant decrease in proliferation in adiponectin treated wild 
type cells and in leptin rescued ob/ob cells treated with adiponectin.  
We also pursued the use of different dietary fatty acids as a means for inducing 
adiponectin production.  We fed swine a diet enriched in the bioactive n-3 fatty acid αLA 
to examine the effects of this fatty acid on adiponectin and to determine if 
eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) can be derived from αLA 
in vivo. We identified a significant increase in the tissue enrichment of αLA, EPA and 
 x 
DPA in a diet dependent manner. However, there was no statistical difference in serum 
adiponectin concentrations or adiponectin transcript abundance among diets.  
Collectively, these studies indicate adiponectin is not instrumental in the 
regulation of adipose tissue deposition in normal mice.  However, adiponectin does retard 
the pro-differentiation phenotype of leptin-deficient stromal vascular cells. Our data also 
indicates that, although αLA is readily converted to EPA and DPA in vivo, the 
concentrations seem insufficient to alter serum adiponectin concentrations in swine. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
Introduction 
In the United States, 30% of all adults are classified as obese [1]. If the current 
trend continues, 50% of the U.S. population will be obese by 2040.  This obese 
population is at an increased risk for the development of low grade inflammation that 
contributes to the development of cardiovascular disease (CVD) and type II diabetes 
mellitus (DM) [2-4].  
Clinical data and findings from various animal models of obesity indicate a strong 
positive correlation between adipose tissue mass and the development of obesity-related 
complications [2].  This association was further strengthened with the identification of 
adipose tissue as an endocrine organ [3].  The endocrine function of adipose tissue 
includes the secretion of pro-inflammatory, anti-inflammatory, and the 
metabolic/appetite-regulating cytokines [4, 5] . Multiple studies have shown that an 
increase in the proinflammatory cytokines tumor necrosis factor alpha (TNFα), 
interleukin 6 (IL6), and monocyte chemotactic protein 1 (MCP1) in adipose tissue are 
involved in the progression of obesity-associated systemic inflammation [6-8] . The 
development of adipose tissue inflammation is also positively correlated with a reduction 
in the concentration of the anti-inflammatory cytokine, adiponectin [9].  Although the 
exact mechanism for the induction of adipose tissue inflammation is not known, the 
leading hypothesis implicates adipocyte cellular stress. The adipocyte can become 
stressed with lipid overload [10, 11], hypoxia [12], and increased protein synthesis, all of 
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which activate a stress response in the endoplasmic reticulum (ER). The induction of ER 
stress leads to the activation of pro-inflammatory pathways in the adipocyte.  
To avoid lipid overload and its associated cellular stress, adipose tissue responds 
by increasing lipid storage through adipocyte hypertrophy. The lipid storage capacity of 
adipose tissue is also increased through hyperplasia and differentiation of preadipocytes 
into mature adipocytes. Furthermore, adipose tissue can also decrease circulating lipid 
concentrations through the production of  hormones that induce lipid oxidation and 
suppress appetite [13]. When adipose tissue is no longer able to accommodate increased 
lipid storage or stimulate the removal of lipid through oxidation, stress-induced 
inflammation occurs. If this cellular stress is not alleviated, cell death quickly follows, 
and macrophage recruitment and infiltration into adipose tissue is increased [14]. 
Current literature indicates adipose tissue inflammation can be alleviated by the 
anti-inflammatory cytokine adiponectin. When adiponectin concentrations are restored to 
a normal concentration in obese animals, low grade inflammation is reduced. Correction 
of hypoadiponectinemia or the induction of hyperadiponectinemia both increase PPARα 
activation and subsequent transcription of lipid-oxidizing enzymes in obese animals and 
in in vitro [15-17]. Adiponectin serum concentrations can be altered with administration 
of exogenous adiponectin and through the activation of the transcription factor PPARγ 
[18].  Activation of PPARγ can be accomplished by administration of the synthetic 
ligands, thiazolidinediones (TZD); however, TZD adversely promote the expansion of 
adipose tissue [19, 20].  A more desirable means for activation of PPARγ is through 
consumption of its natural activators, fatty acids.  
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Neschen et al. showed an increase in PPARγ activation and subsequent increase 
in adiponectin with the consumption of n-3 fatty acids [21]. Previous literature also 
indicates that n-3 fatty acids have anti-inflammatory properties independent of 
adiponectin. Therefore, n-3 fatty acid tissue enrichment through supplementation appears 
to be a promising treatment option for inflammation. However, it remains to be 
determined if consumption of high concentrations of αLA results in the desired effect or 
if DHA and EPA consumption is required. Furthermore, data on the role of αLA 
conversion to EPA and DHA in non-hepatic tissue is sparse and requires further 
investigation in non-rodent models. 
The accepted dogma for correction of obesity-associated inflammation by 
adiponectin revolves around the inhibition of TNFα signaling and production, nuclear 
factor kappa B (NFκB) activity, and removal of adipocyte stress through increasing lipid 
oxidation. However, in 2007 Kim and colleagues published data indicating the 
overexpression of adiponectin decreases inflammation and lipid mediated stress by 
promoting adipose tissue proliferation in leptin-deficient mice [22].  Since 2007, there 
have been limited follow up data to support the role of adiponectin in adipocyte 
proliferation, and it is not definitively known if adiponectin is directly involved in 
adipose tissue growth.  
The previously described data indicate adipose tissue is a key player in the 
exacerbation of low grade systemic inflammation present in obesity. Furthermore, these 
studies indicate adiponectin is an important in the resolution and prevention of 
inflammation. However, the current methods of increasing adiponectin production in vivo 
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rely on pharmaceutical means that have significant side effects. The identification of n-3 
fatty acids as natural ligands for the PPARγ receptor indicates dietary supplementation 
may be a feasible method for increasing serum adiponectin concentrations. To address 
the current gaps in the understanding of the influence adiponectin has in body 
composition, we examined the body composition of adiponectin null mice after being fed 
a high fat diet. Furthermore, we tested the role of adiponectin on proliferation and 
differentiation of subcutaneously derived leptin-deficient preadipocytes. The last key 
point addressed in our research was the feasibility of n-3 fatty acid tissue enrichment and 
modulation of adiponectin concentrations with canola oil supplementation.  
Objectives and Aims 
Our objective was to identify the role of adiponectin in adipose tissue expansion 
and to identify the role of dietary n-3 FAs in the induction of adiponectin. This work was 
focused around the central hypothesis that adiponectin stimulates preadipocyte 
proliferation and differentiation and that the dietary supplementation of αLA will increase 
tissue enrichment of EPA and DHA which in turn stimulate adiponectin production. 
Together these experiments contribute to the knowledge base on adiponectin function and 
may lead to the recommendation for increasing n-3 fatty acid in the diet as a means to 
increase adiponectin concentrations and to establish healthier adipose tissue. My specific 
aims (I) determine if dietary αLA is converted to EPA and DHA in vivo and if these 
products are significantly enriched in tissue.  We also wish to determine if these fatty 
acids result in an increase in transcriptional abundance or circulating concentrations of 
adiponectin.  The second aim was to (II) identify the role of adiponectin in body 
 5 
composition of mice, with specific emphasis on lipid storage capacity.  Lastly, we sought 
to (III) identify the role of adiponectin in the activation of proliferation and 
differentiation in primary leptin-deficient mouse stromal vascular cells. 
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CHAPTER 2. REVIEW OF LITERATURE 
Co-morbidities and the Link to Adipose Tissue 
Obesity is associated with the development of type II diabetes, cardiovascular 
disease, and cancer [1, 2]. Although these co-morbidities are multifactoral disease states, 
their high prevalence in obesity suggests that excess adipose tissue is a contributing 
factor. Examination of adipose tissue in obese humans and in animals with one or more 
co-morbidities indicates that this tissue can develop low grade inflammation. 
  Persistent inflammation and subsequent greater rates of lipolysis in adipose 
tissue can lead to systemic metabolic dysfunction [1, 3, 4].  During metabolic 
dysfunction, glycolytic tissue becomes insulin resistant and type II diabetes results. 
Furthermore, the unabated systemic inflammation present during metabolic stress can 
lead to the propagation of cardiovascular disease [5]. It is clear from the literature that 
obesity is a serious health concern and that adipose tissue is a key factor in the 
progression of this disease state and its co-morbidities.  
The Role of Adipose Tissue in Homeostasis 
 Adipose tissue is an essential organ system for the storage of energy in animals 
that experience periods of starvation. Even when food is plentiful, adipose tissue is 
necessary for the maintenance of metabolic homeostasis. Without adipose tissue, 
metabolic crises develop.  For instance, lipodystrophy mouse models develop severe 
diabetes when allowed to over consume calories. There are multiple mouse models that 
are lipodystrophic, with all having serum concentrations of glucose that are 2 -3 times 
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normal and insulin 2-400 times normal [6-11]. Furthermore, lipodystrophy is associated 
with increased serum triacylglycerol and free fatty acids. The metabolic profile of the 
autosomal recessive lipodystrophy mouse model is similar to and indicative of insulin 
resistance.  
 When adipose tissue is transplanted from a healthy donor mouse, serum 
glucose and insulin concentrations return to normal in lipodystrophy mice. Likewise, 
serum triacylglycerols and free fatty acids are significantly reduced compared to 
lipodystrophy animals without adipose tissue transplantation but do not equal wild type 
concentrations after 6 weeks post surgery [12]. The increase in serum glucose, insulin, 
triglycerides and free fatty acids seen in lipodystrophy mice is similar to the description 
of lipotoxicity as described by R. Unger in multiple reviews [13-18].   
 Lipotoxicity is characterized as the deleterious effects of lipid accumulation 
in non-adipose tissue depots.  Lipid accumulation in the key metabolic tissues of liver, 
muscle, and pancreas leads to insulin resistance. Unlike other tissues, the unique 
physiology of adipose tissue allows for lipid accumulation without the development of 
metabolic disturbance.  A classical model of lipid-induced disease in non-adipose tissue 
is the deposition of fatty acid in liver, which is accompanied by a rise in the activation of 
the transcription factor, nuclear factor κ B (NFκB) [19].  Active NFκB translocates to the 
nucleus and initiates the transcription of inflammatory cytokines.  Tumor necrosis factor 
α (TNFα) is an inflammatory cytokine under the control of NFκB that increases in the 
liver during lipid overload [19]. TNFα inhibits insulin receptor substrate (IRS) by 
promotion of phosphorylation on serine residues, which leads to insulin resistance [20]. 
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Insulin resistance in liver tissue exacerbates dyslipidemia and increases the susceptibility 
for the development of cardiovascular disease [21]. Furthermore, uncontrolled lipid 
accumulation in the liver increases the activation of an apoptotic stress response, which 
leads to fibrosis and cirrhosis [22]. 
 Similarly, fatty acid accumulation in muscle tissue disturbs insulin receptor 
signaling as observed in skeletal muscle cells treated with saturated fatty acids, likely 
through the production of ceramide [23].  Ceramide interferes with metabolism by 
decreasing insulin receptor signaling through inhibition of protein kinase B (AKT/PKB) 
and inhibition of mitochondrial function. Ceramide also increases apoptosis through 
induction of the pro-apoptotic protein BAX [24]. Additively, lipid accumulation in 
muscle corresponds with an increase in TNFα and its metabolic effects. Cumulatively, 
lipid overload in skeletal muscle causes insulin resistance that reduces glucose uptake 
that may cause serum concentrations of glucose to escalate.  
 The most metabolically devastating effect of ectopic lipid accumulation is 
in the pancreas. Excess lipid in pancreatic β-cells decreases the production of essential 
proteins involved in insulin secretion, such as GLUT2 and glucokinase [25].  As 
described in other tissues, lipotoxicity can progress to cell death in the pancreas. 
Pancreatic β-cell death results in insulin-dependent diabetes, which leads to death if 
exogenous insulin is not provided [26].  Although the previously described tissue-specific 
effects of lipid accumulation were not examined in lipodystrophy models, the systemic 
metabolic profile of the lipodystrophy mouse model exemplifies the protective effects of 
adipose tissue against ectopic lipotoxicity and insulin resistance [27].  
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Adipose Tissue Physiology 
 The cell types present in adipose tissue can be separated into two distinct 
cell populations: adipocytes and cells of the stromal vascular fraction (SVF) [28, 29]. 
Adipocytes are the largest cells in adipose tissue and are responsible for lipid storage.  
Stromal vascular cells consist of myeloid immune cells, pre-adipocytes, and endothelial 
cells [29, 30]. The cells of the SVF of adipose tissue also includes multipotent 
mesenchymal stem cells and hematopoetic stem cells derived from bone marrow [31, 32]. 
Resident stem cells in the SVF of adipose tissue are able to differentiate into adipocytes, 
chondrocytes, osteoblasts, and myocytes [31, 33-35]. The presence of precursor cells in 
adipose tissue provides a suitable environment for rapid tissue growth.  
 The adipocytes and the cells of the SVF communicate through extensive 
paracrine signals. When mature adipocytes hypertrophy to maximal size, pro-adipogenic 
paracrine signals are secreted to recruit the expansion and differentiation of the 
preadipocyte population.  Likewise, adipocytes and SVF cells communicate through the 
secretion of inflammatory hormones. The paracrine system of cellular cross talk in 
adipose tissue allows adipose tissue to adapt through hypertrophy (adipocyte expansion), 
hyperplasia (expansion of preadipocyte population), and differentiation (commitment of 
precursor cells to adipocyte phenotype).  
Adipose Tissue Hypertrophy, Hyperplasia, and Differentiation 
 Traditionally, the number of adipocytes present in an adipose tissue depot 
were thought to remain unchanged after establishment early in life [36].  However, 
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adipose tissue is now accepted as a highly adaptable tissue [37].  In times of excess 
energy balance, adipocyte hypertrophy is utilized to increase lipid storage as 
triacylglycerol (TAG) [38]. Adipocyte hypertrophy involves the increase in lipid droplet 
growth and overall cell size. It is suspected that adipocytes have limited size potential. 
When expansion of the adipocyte encroaches on the upper limit of size, the adipocytes 
begin to secrete hormonal signals to promote the proliferation (mitotic replication) of 
preadipocytes and terminal differentiation into adipocytes [39-44].  
 The information on preadipocyte determination and proliferation is scarce. 
Only recently has part of the transcriptional control of determination been investigated 
and linked to the transcription factor Zfp423 [45].  Contrary to the paucity of data on the 
signaling pathways of determination and proliferation, preadipocyte differentiation is 
well documented in the literature. Differentiation of preadipocytes begins with cellular 
growth arrest and clonal expansion of preadipocytes [46-48]. Previous literature indicates 
preadipocyte cell lines require clonal expansion for terminal adipocyte differentiation 
[49-54].  Following clonal expansion the cells begin to produce adipocyte specific 
proteins and develop the characteristic lipid droplets.  
 The adipocyte phenotype is associated with proteins that mediate lipid 
metabolism and transport, insulin sensitivity, and increase the production of adipocyte 
specific proteins. Because of the broad range of proteins that are indicative of adipocyte 
differentiation, it is easier to measure the concentrations of the transcription factors 
controlling the expression of these proteins. The key transcription factors involved in 
differentiation are: Ccaat-element-binding protein alpha (C/EBPα), Ccaat- element-
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binding protein delta (C/EBPδ), Ccaatt-element-binding protein beta (C/EBPβ), and 
peroxisome proliferator activated receptor gamma (PPARγ ) [46, 55]. Previous literature 
has highlighted the involvement of many other transcription factor families in the 
regulation of adipogenesis. The list of pro-adipogenic transcription factors and co-
activators includes: sterol response element-binding protein-1c (SREBP1c), Kruppel-like 
factors (KLF15, KLF5, and KLF6),  TRAP220, TATA-binding protein-associated factor-
8 (TAF8), and cyclin D3-cyclin-dependent kinases (CDK6 and CDK4). On the other 
hand, anti-adipogenic factors include: PREF1, transcription factor homologous to 
CCAAT-enhancer binding protein (CHOP), C/EBPγ, KLF2, KLF7, and GATA2/3.  
Interestingly, all of the previously mentioned factors influence differentiation through the 
modulation of the PPAR and C/EBP families of transcription factors. For instance KLF2 
and GATA2/3 inhibit PPARγ, KL5 and KLF15 increase PPARγ activation [56]. Due to 
the breadth of literature on transcriptional control of differentiation, only the main 
transcription factors C/EBPα, C/EBPδ, C/EBPβ, and PPARγ are discussed in detail.  
 Terminal adipocyte differentiation is the result of the combined suppression 
of anti-adipogenic signals and the induction of proadipogenesis and as such occurs in 
multiple steps where the activation of one factor is dependent on the prior activation of 
another. Adipocyte differentiation can be separated into early and late stages. Early stages 
of differentiation are associated with an increase in the transcription factors C/EBPβ and 
C/EBPδ [57, 58].  These early phase transcription factors are responsible for the 
production of the late phase transcription factors PPARγ and C/EBPα. Once C/EBPβ/δ 
increase the late phase factors, their concentrations begin to subside. Elevation of 
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C/EBPα and PPARγ concentrations are essential to the terminal differentiation of 
preadipocytes as indicated by knockout models. C/EBPα null mice fail to develop 
adipose tissue where as the use of C/EBPα antisense mRNA inhibits differentiation [59, 
60].  Similarly, PPARγ null embryonic stem cells fail to differentiate under normal 
induction techniques [61]. Conversely, overexpression of PPARγ results in differentiation 
of cells in the absence of hormonal signal [62]. 
 The characterization of preadipocyte differentiation transcriptional 
regulation and morphology has been investigated mostly in in vitro models which require 
hormonal induction of the adipogenic phenotype [63, 64]. The most commonly used 
hormones for the development of an adipogeneic phenotype are: glucocorticoids, 
phosphodiesterase inhibitors, insulin, and thiazolidinediones [63-65].  Although the 
hormonal cocktail for differentiation of preadipocytes in vitro is well established, the in 
vivo hormonal cascade is poorly characterized. 
Endocrine Function of Adipose Tissue 
Prior to the discovery of the adipose tissue specific protein leptin in 1994, adipose 
tissue was viewed exclusively as a storage depot for lipid. Leptin was the first cytokine 
discovery of many in adipose tissue that led to the establishment of this tissue as an 
endocrine organ [66].  The list of bioactive molecules originating from adipose tissue is 
currently well over 100 and now includes bioactive lipids in addition to cytokines and 
chemokines [67, 68].  The generalized physiological effects of adipose tissue-derived 
hormones include the regulation of appetite, inflammation, and metabolism.  
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Many of the molecules derived exclusively in adipose tissue exhibit strong 
relationships with obesity and adipose tissue mass.  Three key adipokines that are 
inflammatory and are increase during obesity are: TNFα, Interleukin-6 (IL6), and 
monocyte chemotactic protein 1(MCP1).  TNFα is secreted from the stromal vascular 
fraction of adipose tissue, primarily from adipose tissue macrophages [69]. TNFα is a 
potent insulin signal disruptor through mediation of phosphorylation on serine of the 
insulin receptor substrate and activation of phosphotyrosine phosphatases [70]. TNFα 
signals through the secondary signaling proteins mitogen-activated protein kinases 
(MAPK), p38 MAPK, and extracellular signal-regulated kinases (ERK) [71-73]. TNFα 
also decreases the production of anti-lipolytic proteins and causes adipocytes to lose their 
lipid droplet and stop expressing PPARγ and C/EBPα, which creates a fibroblast like 
non-adipocyte cell [74]. The combined effects of IRS inhibition, removal of lipolytic 
signals, and its role in adipocyte dedifferentiation make TNFα an inducer of lipotoxicity. 
IL6 is a proinflammatory cytokine secreted from adipocytes and the SVF of 
adipose tissue [75]. IL6 signals through JAK/STAT receptors and disrupts insulin 
signaling in muscle, liver and adipocytes [76].  The activation of the JAK/STAT receptor 
complex by IL6 increases protein kinase-C (PKC) and suppressor of cytokine signaling-3 
(SOCS3), which stimulates the phosphorylation of inhibitory serines on the IRS and 
prevents the phosphorylation of tyrosine on the IR, respectively [77-79].  Furthermore, 
IL6 has been shown to have lipolytic action in adipose tissue a condition that contributes 
to the development of lipotoxicity [80]. 
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Adipose tissue also secretes the chemotactic protein MCP1, a monocyte 
recruitment signal [81]. Like IL6 and TNFα, an increase in MCP1 concentrations is 
associated with a decrease in insulin sensitivity.  However, MCP1 is not directly 
responsible for insulin resistance; rather the subsequent infiltration of macrophages is a 
more likely culprit [82]. Infiltration of adipose tissue by cytokine-secreting mature 
macrophages recruited by MCP1 perpetuates the inflammatory milieu in adipose tissue.  
Leptin, the first cytokine characterized in adipose tissue, has a role in appetite, 
metabolism, and inflammation [83-87].  The primary location of leptin action is the 
hypothalamus where it suppresses appetite and activates the central nervous system [88, 
89]. Thus, leptin concentrations are directly correlated to adipose tissue mass and its 
concentrations increase during obesity in an effort to suppress appetite [90, 91].  Leptin 
also has physiological functions in peripheral tissues that include metabolism and 
immunity. In peripheral tissue, leptin influences metabolism through phosphorylation of 
AMPK and regulation of gene expression through STAT3 [92-94]. Leptin-activated 
AMPK increases the metabolism of lipid (i.e., increased fatty acid oxidation) [92] and its 
storage by promoting a pro-adipogenic environment [95].  
Adiponectin - Discovery and characterization 
Adiponectin was identified by four independent groups between 1995-1996 and 
appears in the literature under multiple names (Acrp30, apM1, AdipoQ, GBP28, 
adiponectin) [96-99]. The crystal structure of adiponectin was reported in 1998, and, from 
this structure three distinct domains were identified: a collagenous domain, a variable N-
terminal, and a C-terminal globular domain [99]. Previous literature indicates that the 
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collagenous domain of adiponectin is subject to post-translational modifications 
(glycosylation and hydroxylation) [100, 101].  Following these modifications, 
adiponectin monomers oligomerize to form a trimeric complex through non-covalent 
interactions in the collagenous domains. Higher order adiponectin isoforms (up to 20 
monomers or 7 trimers) are formed by the aggregation of trimers via disulfide-bonds at 
Cys-39 of the N-terminus domain [100, 102]. Both post-translational modification and 
oligomerization of adiponectin is reliant on the retention of adiponectin in the adipocyte 
via the binding protein Erp44 [103].  Following multimerization, adiponectin is released 
from Erp44 by Ero1-Lα and secreted. Due to the requirement for intracellular retention in 
the adipocyte, high molecular weight (HMW) isoforms of adiponectin do not develop 
from monomers or trimers in circulation [104]. Interestingly, circulating concentrations 
of HMW adiponectin can be increased with the treatment of PPARγ agonists [105, 106]. 
The increase in adiponectin by PPARγ agonists was previously attributed to the induction 
of transcription (PPARy is a transcription factor that regulates adiponectin expression).  
However, recent evidence suggests that TZDs (PPARγ agonists) promote an increase in 
adiponectin secretion from adipocytes by decreasing the intracellular binding protein 
ERp44 while increasing the cleavage protein Ero1-Lα [103]. 
As a result of the complex post-translational oligormerization of adiponectin, 
multiple molecular weight isoforms of adiponectin are present in the sera. The four 
commonly described isoforms consist of the most abundant and biologically active high 
molecular weight isoform (HMW, >250Kda); as well as the medium molecular weight ( 
MMW, hexamer, 180kDa ), low molecular weight (LMW, dimer and trimer,70-90kda) 
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and the globular form [107].  The globular isomer, which makes up less than 1% of 
circulating adiponectin, is a proteolytic cleavage product consisting of the c-terminal end 
of an adiponectin trimer [108]. Although there are many circulating isoforms of 
adiponectin, there are only two adiponectin receptors (AdipoR1 and AdipoR2) 
responsible for their biological activity[109]. 
Adiponectin Receptors and Signaling 
 
Adiponectin binds to unique seven transmembrane receptors that exist in two 
highly homologous (66.7% identity) isoforms, AdipoR1 and AdipoR2 [110].  Unlike the 
distantly related family of traditional G-coupled protein receptors (GCPRs), the 
adiponectin receptors have a unique rotated configuration in the plasma membrane. The 
carboxy terminal of the receptor is located in the extracellular space, whereas the N-
terminal is on the cytosolic side of the plasma membrane (Figure 1) [110].  
Figure 1.  Illustration of the adiponectin receptors. 
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Activation of the adiponectin receptors occurs when adiponectin binds the 
carboxy end of the receptor [111]. The activation of AdipoRs does not result in the 
interaction with G proteins like traditional G-coupled protein recpetors (GCPR). Until 
recently the secondary signaling molecule for the adiponectin receptor was unknown. 
The adiponectin receptor signaling pathway was recently expanded to include 
APPL1 (adaptor protein containing phosphotyrosine binding, pleckstrin homology 
domains, and leucine zipper 1), the first adaptor protein to interact with the ligand bound 
AdipoRs [111].  APPL1 is the bridge between the AdipoRs and downstream effector 
proteins, like Rab5 (a small GTPase) and AMPK. Rab5 is involved in the 
phosphorylation of AKT and the subsequent translocation of GLUT4 to the cell 
membrane [112]. APPL1-mediated phosphorylation of AMPK results in the inhibition of 
IKK of the NFkB pathway [113], increase in GLUT4 translocation, increase in insulin 
sensitivity, and promotion of fatty acid oxidation. APPL1 is also speculated as promoting 
cellular proliferation through AKT-mediated reduction in BAD/Bcl2 apoptotic signals, as 
well as activation of  the cell proliferation signal ERK 1/2 [114].   
Although APPL1 interacts with both AdipoR1 and AdipoR2, activation of either 
receptor isoform results in a distinct physiological outcome. AdipoR1 activation is 
generally associated with insulin-sensitizing effects mediated through the 
phosphorylation of AMPKα, AdipoR2 is commonly attributed to the activation of PPARα 
and the subsequent production of lipid-oxidizing enzymes [115, 116].   
A third receptor for adiponectin was proposed to be T-cadherin by the Lodish 
group.  This group demonstrated successful binding of trimeric adiponectin to the 
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adhesion molecule T-cadherin [117].  It is unknown if the binding of adiponectin results 
in intracellular signaling given that T-cadherin is an adhesion molecule with a limited 
intracellular domain. A more likely function of T-cadherin is to hold adiponectin closely 
to the cell surface where it can interact with either adiponectin receptor 1 or receptor 2.    
Physiological Effects of Adiponectin Signaling Varies by Tissue  
The diverse physiological effects mediated by adiponectin are the result of the 
tissue distribution of the AdipoRs.  AdipoR1 is ubiquitously distributed in tissues and 
highly expressed in skeletal muscle. The AdipoR2 is primarily expressed in abundance in 
the liver [110]. To understand adiponectins metabolic effects it is important to 
characterize its effects in the three key tissues where adiponectin has the greatest 
physiological impact in regards to obesity: muscle, liver, and adipose tissue. 
Adiponectin and Muscle. Adiponectin increases glucose uptake and fatty acid 
oxidation in  muscular tissue [93, 118]. Increased glucose uptake in muscle is the result 
of AMPKα phosphorylation through AdipoR1 activation by globular adiponectin [116]. 
Phosphorylated AMPKα increases glucose uptake through a reduction in the inhibitory 
phosphorylation of serine on insulin receptor substrate 1 (IRS1) and activation of glucose 
transporter 4 (GLUT4) [119].  Activation of adiponectin receptors in muscle also leads to 
the activation of p38 mitogen-activated protein kinase (MAPK) by AMPK 
phosphorylation [120].   p38 MAPK phosphorylates and activates PPARα [110, 121]. 
Active PPARα translocates to the nucleus and increases the transcription of fatty acid 
oxidative enzymes (acetyl-CoA oxidase (ACO) and carnitine palmitoyltransferase 1 
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(CPT1)) [115]. Therefore, the main effects of adiponectin in skeletal muscle tissue are to 
promote insulin stimulated glucose uptake and increase fatty acid oxidation.  
Adiponectin and Liver. In the liver, full length adiponectin reduces glucose 
production through two distinct pathways [93, 122]. Specifically, the AdipoRs 
phosphorylate AMPK, which causes an attenuation of phosphoenolpyruvate 
carboxykinase and glucose-6 phosphatase expression [123]. Furthermore, active AMPK 
phosphorylates acetyl-CoA carboxylase (ACC). Phosphorylated ACC results in the 
inhibition of ACC enzyme function, inhibiting de novo lipogenesis  [93, 124]. 
Interestingly, the liver has a high concentration of AdipoR2 isoform, which is associated 
with the activation of PPARα. As described for skeletal muscle, PPARα increases the 
oxidative potential of liver tissue. Therefore, the main metabolic effect of adiponectin in 
the liver is to decrease gluconeogenesis and de novo lipogenesis while increasing fatty 
acid oxidation.  
Adiponectin and Adipose Tissue. Similar to muscle and liver tissue, the 
activation of AdipoR1 by globular adiponectin results in an increase in glucose uptake 
through AMPK phosphorylation [125]. Adiponectin-stimulated AMPK increases the 
translocation of GLUT4 to the membrane of adipocytes [112].  AMPK phosphorylation 
in adipose tissue promotes the phosphorylation and inhibition of ACC, thus reducing de 
novo lipogenesis[125].  Accompanying the decrease in de novo lipogenesis, adiponectin 
signals through p38 MAPK to activate PPARγ coactivator-1 (Pgc-1). Activation of PGC1 
increases FA oxidation [126]. Adiponectin signaling in adipose tissue also activates 
PPARα inducing β-oxidation in the adipocyte. Depending on the species, adiponectin 
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may also decrease the de novo lipogenesis in adipose tissue as seen in liver tissue.  For 
instance, swine adipose tissue is responsible for almost 95% of de novo lipogenesis 
whereas humans rely on adipose tissue for less than 5% of de novo lipogenesis. 
Serum Adiponectin Concentrations. Clinical investigations have identified a 
negative correlation between serum adiponectin concentrations and body weight [127]. In 
healthy non-obese humans, serum adiponectin circulates at 2.0 µg/ml to 17.0 µg/ml, 
depending on gender and age, with an average of 9.0 µg/ml. [127-130]. These 
concentrations drop to an average of 4.0 µg/ml in obese individuals and are associated 
with increased disease risk [127].  Mouse adiponectin concentrations are also greater in 
female, lean, and younger animals.  Healthy mice have serum adiponectin concentrations 
ranging from 3-15 µg/ml [105, 131, 132]. Likewise, swine serum adiponectin 
concentrations are close to humans with concentrations of 5-30 µg/ml (unpublished data 
from our laboratory). 
Adipose Tissue Depot Differences 
 Each of the multiple adipose tissue depots have distinct physiological profiles and 
should be considered distinct tissues. The two general locations of adipose tissue 
commonly described in the literature are subcutaneous and visceral.  Within the visceral 
compartment, adipose tissue depots can be separated into omental or mesenteric. 
Physiological differences in adipose tissue depots can range from lipolytic sensitivity to 
increased risk of developing insulin resistance [133-137]. 
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 The most notable difference in adipose tissue depots is their cytokine secretion 
capabilities. In regards to the investigation of obesity-related inflammatory cytokines, a 
distinct profile exists for each adipose depot.   Human omental fat secretes almost 3 times 
the amount of IL6 than cells from the subcutaneous depot [138]. Likewise, MCP1 is 
secreted in greater concentrations from visceral adipose tissue than subcutaneous adipose 
tissue in humans [139]. Also, the production and secretion of the two key adipokines 
leptin and adiponectin in humans are greater in subcutaneous adipose tissue compared 
with visceral tissue [140-143]. 
 The plasticity of adipose tissue depots can also differ.  Wang et al. and Lau et al. 
identified a greater propensity for adipogenesis in perirenal depots versus epididymal 
adipose tissue [144, 145].  Likewise, the expansion of subcutaneous adipose tissue is 
mediated primarily by adipogenesis whereas expansion of visceral adipose tissue is 
associated more with adipocyte hypertrophy [146]. Similarly, adipose tissue depots in 
rats differ in their method of expansion; subcutaneous adipose tissue and retroperitenal 
adipose are more likely to increase in adipocyte number whereas mesenteric and 
epididymal adipose increases cell volume [147]. Interestingly, omental adipose tissue of 
humans is less responsive to PPARγ agonists in regards to differentiation compared with 
subcutaneous adipose tissue [148] but the SVF cell number of the subcutaneous depot of 
obese humans is lower than that of the omental or mesenteric adipose tissue depots [133]. 
  Metabolic function also varies across adipose tissue depots.  Adipocytes from 
visceral depots are documented as having greater lipolytic rate than subcutaneous depots 
[134-136].  Furthermore, mesenteric adipose tissue is less sensitive to insulin and 
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lipolytic hormones [147, 149]. Similarly, human omental adipose tissue have a lower 
efficiency in insulin signaling than visceral adipose tissue as observed by a decrease in 
GLUT4 and an increased abundance of the lesser efficient insulin receptor splice variant 
[137].  
Dysfunction of Adipose Tissue (causes, consequences, and adiponectin) 
Causes of Adipose Tissue Dysfunction 
The primary insult responsible for the initiation of inflammation in adipose tissue 
is still under investigation. Obesity creates a lipid-rich environment in adipose tissue.  
This condition increases adipose tissue susceptible to the development of inflammation. 
The inflammatory profile (e.g., cytokines, transcription factor activation) present during 
adipose tissue dysfunction indicates endoplasmic reticular stress (ER stress) may be 
involved.  
Endoplasmic Reticulum Stress 
The ER is an organelle responsible for the processing of cellular proteins.  
Dysfunction of the ER results in misfolded and non-functional proteins. Accumulation of 
misfolded proteins in the ER leads to inflammation and apoptosis. The unfolded protein 
response (UPR) is a key rescue system used by the cell to correct ER stress [150]. The 
UPR utilizes the following signaling proteins to alleviate stress; PKR-like ER-localized 
eIF2α kinase PERK, IRE-1, and activating transcription factor 6 (ATF-6). Briefly, all of 
these proteins are associated with the ER membrane and are activated when misfolded or 
non-functional proteins accumulate in the ER lumen [150, 151]. PERK and IRE-1 both 
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autophosphorylate and activate subsequent signaling pathways. ATF-6 is a nuclear 
transcription factor that must be modified in the golgi prior to translocation to the nucleus 
[151, 152]. PERK signals the phosphorylation and inhibition of translation factors like 
eIF2α, IRE-1 activates XBP1, which, in turn, mediates an increase in the transcription of 
protein chaperones. An increase in the production of protein chaperones enhances the ER 
secretion of proteins and promotes ER biogenesis [152, 153].  Chaperone proteins are 
also increased via ATF-6 transcriptional control.  
The inflammation present during UPR is mediated through IRE-1 and PERK. 
IRE-1 activates the transcription factors c-Jun N-terminal kinase (JNK), NFkB pathways, 
while PERK only activates NFkB. Translocation of the transcription factors JNK and 
NFkB to the nucleus results in the transcription of pro-inflammatory proteins (IL6, IL8, 
TNFα, and MCP1) [154-156]. Reactive oxygen species (ROS) generated as byproducts of 
increased disulfide bond formation during UPR also causes inflammation [154, 156, 
157]. 
Several of the inflammatory proteins that are elevated with ER stress are also 
present during obesity. These inflammatory proteins include IL6, TNFα and MCP1. In 
addition, obesity is also associated with elevated ROS. Similarly, elevated PERK and 
JNK activation have been detected in the adipose tissue of obese mice [158]. The link 
between ER stress and inflammation is complicated by the observation that the UPR 
activates inflammation and is induced by inflammation.  Xue et al. identified an increase 
in the UPR  in murine fibrosarcoma cells treated with ROS and TNFα [159].  These 
findings indicate that ER stress may be initiated by inflammation. ER stress-induced 
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inflammatory cytokines may cause a feed forward response  resulting in a cyclical 
inflammatory cascade.  
Unresolved low grade inflammation is a hallmark indicator of increased 
susceptibility for the progression of insulin resistance in obese animals.  Nakatani et al. 
linked ER stress with a decrease in insulin sensitivity in obese mice [160]. Furthermore, 
ER stress may be involved in the progression of adipose tissue mass accretion. Scheuner 
et al. developed a knockout mouse model that allowed for non-interruptible protein 
synthesis [161]. This model causes a protein overload and subsequent ER stress [161]. 
When Scheuner et al. exposed these ER stress susceptible mice to a high fat diet, they 
developed almost twice the adipose tissue mass of the wild type controls [162]. The 
evidence presented here indicates ER stress is likely a key player in the progression to 
physiological dysfunction during the obese state.  
Consequences of Adipose Tissue Dysfunction 
Inflammation 
Clinical observations indicate a positive correlation between obesity and systemic 
inflammation [163, 164]. In the commonly used mouse obesity models, adipose tissue 
inflammation has been suggested as a contributing factor of systemic inflammation.  
Furthermore, in vitro studies demonstrate that the 3T3L1 adipocytes secret inflammatory 
cytokines when subjected to extended lipid filling, saturated fatty acid (SFA), or an 
inflammatory agent like lipopolysaccharide (LPS) [165-167].  As mentioned previously, 
the primary pro-inflammatory cytokines of interest in adipose tissue are IL6, TNFα, and 
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MCP1.  These inflammatory cytokines have the distinct ability to modulate metabolism 
and promote macrophage infiltration into adipose tissue.  
The Role of Adipocytes, Pre-adipocytes, and Immune Cells in Adipose Tissue 
Dysfunction 
Fain, Ross and McIntosh [168] propose that cells located in the SVF of adipose 
tissue are responsible for the majority of the tissue inflammation [69, 169, 170]. Further 
investigation reveals pre-adipocytes and macrophages are the main cytokine secretors in 
the SVF [171]. Although adipocytes are not considered the primary cytokine producers, 
they do have a pivotal role in the initiation of inflammation in the SVF. Adipocyte stress 
results in TNFα and IL6 secretion that stimulates the pre-adipocyte population and 
resident macrophages to produce inflammatory cytokines. The compounding 
inflammation derived from adipocyte and the SVF provides the ideal environment for 
monocyte accumulation within adipose tissue.   
The establishment of an inflammatory macrophage population in adipose tissue 
leads to a cyclic inflammatory milieu and systemic inflammation. Immunohistochemstry 
of adipose tissue has demonstrated that macrophages infiltrate and tend to form a 
“crown” like structure around dying adipocytes that stain negative for perilipin [28].  
Furthermore, Weisberg et al. suggests adipose tissue macrophages are the primary source 
of circulating TNFα in obese animals and are responsible for 50% of the IL6 secreted 
from adipose tissue [171].  
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Insulin Resistance as an Outcome of Inflammation 
A direct consequence of low-grade inflammation is the peripheral down 
regulation of insulin signaling. Inflammation-induced insulin resistance is caused by 
insulin post receptor signaling inhibition [172]. Specifically, excess TNFα results in the 
increased inhibitory phosphorylation of serine on insulin receptor substrate (IRS) [173-
176]. Furthermore, IL6 has similar properties as TNFα in the induction of insulin 
resistance (reduced IRS and GLUT4 activation) in the adipocyte [177].  
The development of insulin resistance in muscle, liver, and adipose tissue is 
detrimental to systemic homeostasis. Inhibition of insulin receptor secondary signaling in 
adipose tissue removes the inhibitory stimulus of hormone-sensitive lipase (HSL). 
Increased fatty acid release by HSL and the  increase in TNFα and/or IL6 stimulated 
lipolysis [178, 179] results in an increase in circulating lipid concentration [180-183]. 
Obesity-associated inflammation also affects adipose tissue lipid storage via inhibition of 
adipose tissue growth. TNFα is also shown to reduce the expansion of adipose tissue by 
inhibiting adipocyte hypertrophy [184]. TNFα also inhibits adipogenic potential through 
a reduction in PPARγ signaling [185-187].  
 Insulin resistance in muscle and liver tissue reduces the amount of glucose 
entering the tissue causing an elevation in serum glucose. An increase in serum glucose 
and lipid that is accompanied by deceased capacity for adipose tissue storage can lead to 
lipotoxicity and its associated complications.  
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Adiponectin and Adipocyte Dysfunction 
Adiponectin has Anti-inflammatory Functions  
Early research on adiponectin identified a domain that is homologous to 
complement protein 1 and a domain with structural similarity to TNFα (hence the early 
name C1q) [98, 99].  Presence of a complement protein homology domain and the 
similarity to TNFα spurred the investigation of adiponectin as an inflammatory protein. 
However, clinical observations identified an inverse correlation between adiponectin and 
mild inflammation, suggesting that adiponectin may repress inflammation [129, 188]. 
Furthermore, adiponectin is reported as reducing the presentation of TNFα-associated 
adhesion molecules in endothelial tissue [189].  Adiponectin is also a known inhibitor of 
NFκB and ROS and promotes the production of the anti-inflammatory cytokine IL10 
[190].   
Adiponectin Regulates Macrophages 
Adiponectin decreases adipose tissue inflammation through the reduction of 
macrophage infiltration [124, 171, 191]. Adiponectin reduces the adipose tissue 
macrophage population through multiple mechanisms: inhibition of monocyte adhesion 
to epithelial membranes, reduction of pro-macrophage cytokines, and retardation of 
macrophage growth.   
The NFkB transcription factor family of cytokines (e.g., MCP1, TNFα, IL6) are 
known inducers of macrophage infiltration into adipose tissue [192-194]. Adiponectin-
documented inhibition of NFkB and its activation of PPARα both reduce the 
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concentration of MCP1 [165, 195]. Adiponectin also down regulates the expression of the 
adhesion molecules VCAM-1, ICAM-1, and E-selectin [189]. These findings are 
corroborated by the observation that immune cell interactions with endothelial cells 
increase during adiponectin deficiency [196].  Lastly, adiponectin inhibits the growth of 
monocytic progenitors and macrophages [197]. Collectively, these key reports indicate 
that adiponectin reduces macrophage infiltration into adipose tissue by inhibiting 
inflammatory cytokines, decreasing binding proteins, and retarding of macrophage 
cellular growth. 
Adiponectin and Metabolism (Prevention of Lipotoxicity and Insulin Resistance)  
Prior to the 2007 publication by Kim et al. [198], the accepted mechanism of 
adiponectin-mediated correction of metabolic disorders was through insulin sensitization 
and the resolution of inflammation. Briefly, reduction of inflammatory cytokines (as 
described in the previous sections) by adiponectin is known to result in favorable insulin 
signaling. When resolution of inflammation is accompanied by the strong glucose 
sensitizing and lipid lowering effects of adiponectin in the liver, muscle, and adipose 
tissue, there is a direct abatement of insulin resistance [199]. However, Kim et al. [198] 
published a report that suggests adiponectin prevents insulin resistance through 
promotion of adipose tissue expansion [198]. This study examined the effects of 
transgenic overexpression of a mutated form of adiponectin in the obesity prone ob/ob 
mouse model. The combination of the ob/ob obesity model and high concentrations of 
adiponectin produced the fattest obese mouse model to date. Intriguingly, these massively 
obese mice presented serum metabolic markers within the normal range. Unlike the 
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transgenic animals, the non-transgenic ob/ob mice exhibited severe metabolic 
disturbances.  The authors concluded that massive expansion of subcutaneous adipose 
tissue allowed for excessive lipid storage, thereby preventing the adverse consequences 
related to lipotoxicity. Although this study was well executed, it failed to address the 
physiological ramifications of a lack of leptin. Furthermore, the author’s state that the 
product of the mutated adiponectin transgene never exited the adipocyte. The authors 
only found native adiponectin in the circulation. The authors disregarded the 
physiological implications of adiponectin intracellular accumulation. Kim et al. [198] 
further concluded that the increase in subcutaneous adipose tissue mass was a result of 
adipogenesis, as based on histological procedures.  This controversial study is one the 
first to suggest adiponectin protects homeostasis through adipose tissue growth. 
However, the research on the effects of adiponectin on adipose tissue morphology is 
limited and contradictory [108, 200, 201].  
Adiponectin: Proliferation and Differentiation 
Evidence from an in vitro 3T3L1 cell culture model indicates proliferation and 
differentiation of preadipocytes is increased with the hyperexpression of adiponectin 
[200]. Furthermore, adiponectin was also shown by Carmo-Avides and colleagues to 
increase the differentiation of human pre-adipocytes [202].  Conversely, a recent 
publication with adiponectin overexpression showed lower adipocyte differentiation 
specific signals (e.g., CEBPα) and an increase in the presence of preadipocyte markers 
(e.g., Pref-1) in the inguinal fat of transgenic mice [203]. Additively, activation of the 
main secondary signaling molecule of the adiponectin receptor, AMPK, has been shown 
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to reduce the expression of the transcription factors PPARγ and CEBPα in mesenchymal 
cells and preadipocytes [204-206].  Supporting these data is the observation that AMPK 
null mice experience increased adipocyte hypertrophy and differentiation [207].  
Methods for Influencing Obesity-Associated Complications 
The modulation of adipose tissue dysfunction and preservation of metabolic 
homeostasis in obesity can be influenced by multiple factors.  Significant weight loss is a 
proven method of obesity management and is a successful way to reduce the 
inflammatory cytokine profile in adipose tissue [208]. Weight loss is attributed to the 
improvement of inflammation, insulin resistance, and the return of normal adiponectin 
concentrations. A secondary approach to reducing obesity associated complications is 
through the consumption or avoidance of specific dietary fatty acids. Fatty acids and their 
metabolic by-products are known effectors of inflammation. A classic representation of 
this is the proinflammatory role of arachidonic acid. There has been a recent focus on the 
biological activity of SFA and the omega 3 (n-3) fatty acids as modulators of obesity 
associated inflammation and metabolic dysregulation  
Dietary Fatty Acids and Obesity 
 Saturated fatty acids, specifically medium chain fatty acids (palmitate, myristic, 
laurate) are described by multiple groups as inducers of adipocyte and macrophage 
inflammation in adipose tissue [73, 166, 209, 210].  Conversely, there is an increasing 
amount of data indicating n-3 fatty acids and monounsaturated fatty acid (MUFA) are 
beneficial for the prevention and resolution of obesity-associated inflammation [211, 
 32 
212]. Consumption of n-3 fatty acids is associated with a reduction in circulating TNFα, 
C-reactive protein (CRP), and IL6 [212-214]. Likewise, dietary MUFA has been shown 
to decrease CRP and IL6 [211].  
 The majority of the current literature studying the anti-inflammatory effects of n-
3 fatty acids focuses on eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
dietary supplementation.  EPA and DHA are the byproducts of alpha-linolenic acid 
(αLA) modification by multiple steps: desaturation, elongation, and oxidation. Briefly, 
the conversion αLA to EPA consists of the desaturation of αLA by Δ6 desaturase, a 
subsequent elongation to 20 carbons, and desaturation by Δ5 desaturase [215]. The 
conversion of EPA to DHA requires the elongation to a 24 carbon chain followed by 
desaturation with Δ5 desaturase and the shortening of the carbon chain to 22 by 
peroxisomal oxidation [215]. Although humans possess the appropriate enzymatic 
machinery for the conversion of αLA to EPA and DHA, the conversion rate is estimated 
to be less than 6% [216]. The limited data on αLA feeding describes an increase in 
plasma and tissue concentrations of EPA, but not DHA [217].  
 Interestingly, not all animals rely on hepatic tissue for the de novo production of 
fatty acids. One key tissue that is commonly overlooked as a site for fatty acid production 
is adipose tissue. Depending on the species, adipose tissue can support up to 90% 
(porcine) or as low as 5% (humans) of de novo lipogenesis [218]. Although not required, 
the presence of de novo lipogenesis and a high concentration of proteins related to lipid 
metabolism make adipose tissue an ideal target for the investigation of fatty acid 
conversion. There is currently a paucity of data on the conversion of αLA to EPA or 
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DHA in adipose tissue. Regardless of the origin of the n-3 fatty acids (in vivo conversion 
or consumed), previous literature indicates n-3 fatty acids are important for prevention 
and resolution of adipose tissue inflammation. 
Effects of FA on Adipose Tissue 
n-3 FA and Membrane Enrichment 
Consumption of a diet rich in n-3 fatty acids results in the enrichment of cell 
membranes through the substitution of n-6 fatty acids [219].  Membrane enrichment with 
n-3 fatty acids has multiple physiological implications, including alteration of the 
functional capacity of receptors located in lipid rafts [220, 221]. It is therefore likely that 
n-3 fatty acids are able to modify insulin or inflammation-associated receptor signaling in 
adipose tissue. Interestingly, the enrichment of n-3 fatty acids does not occur at the same 
rate in all tissues.  Purified EPA supplementation increases plasma phospholipids in 
humans after six weeks of intervention [222]. Enrichment of DHA in adipose tissue, 
skeletal muscle, and cardiac muscle have been shown to occur within three to six months 
in humans supplemented with DHA [217, 223-227]. 
 n-3 FA and Macrophage Recruitment and Inflammation 
Macrophage infiltration into adipose tissue is an indicator of tissue inflammation. 
The macrophage-associated increase in inflammation has been characterized as a 
contributing factor in the development of insulin resistance [228]. Enrichment of the 
cellular environment whether in vivo or in vitro with n-3 fatty acids reduces inflammation 
and inhibits immune cell interaction with adhesion molecules, preventing monocyte 
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infiltration [229-232]. Furthermore, n-3 fatty acids are able to decrease the inflammatory 
contribution of resident tissue macrophages. Novak et al. showed an inhibition of NFκB 
pathway by n-3 fatty acids in culture using LPS-stimulated macrophages [231]. Likewise, 
Fujisaka et al. identified a phenotypic switch in resident macrophages from M1 
(associated with the proinflammatory cytokines TNFα, IL6, and MCP1) to M2 (produce 
anti-inflammatory cytokines IL10 and IL1 receptor antagonist) with n-3 supplementation 
[81, 230].  Similarly, purified EPA supplementation suppresses macrophage 
inflammation in obese animals and increases the secretion but not the transcription of 
adiponectin [233]. Conversely, multiple groups have reported that supplementation of n-3 
fatty acids increases PPAR nuclear receptor activation and subsequent adiponectin 
transcript abundance [234-236]. 
n-3 FA and  Peroxisome Proliferator Activated Receptors  
The n-3 fatty acids EPA and DHA have been shown to increase the expression of 
adiponectin through activation of the PPARγ nuclear receptor [237]. Neschen et al. 
identified an increase in adiponectin in mice fed n-3 fatty acids and was able to abolish 
this increase with PPARγ inhibitors [238]. Furthermore, Banga and colleagues showed an 
increase in adiponectin by DHA activation of PPARγ in 3T3L1 adipocytes [239]. 
Interestingly, n-3 FA also activate the PPARα nuclear receptor [237].   PPARα 
controls the expression of oxidative enzymes [240]. As described previously, adiponectin 
is also able to activate PPARα [116]. The theoretical combined action of n-3 fatty acid 
stimulation of PPARα and the secondary stimulation through adiponectin (increased by 
PPARγ activation) would present a strong signal for increased fatty acid oxidation.  
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These effects were described by Flachs et al. in male mice consuming n-3 fatty acids. 
Flachs et al.[234] identified a threefold increase in mitochondrial biogenesis and a 
significant increase in the oxidation of palmitate in the n-3 treatment group [234].  
n-3 FA: Resolution of Serum Inflammation and an Increase in Glucose Uptake 
Supplemental intake of fish oil, which is rich in EPA and DHA, decreases serum 
TNFα and IL1β by approximately 80% in healthy subjects after eight weeks [229]. 
Furthermore, dietary supplementation of n-3 fatty acids protected mice against high fat 
diet-induced adipose tissue inflammation [232]. The reduction of known insulin signal 
disruptors with the supplementation of n-3 fatty acids is also accompanied by an increase 
in GLUT4 transcription and subsequent glucose uptake in the adipose tissue of rats [241]. 
n-3 FA and Adiposity 
Previous research indicates n- 3 fatty acids inhibit the growth of adipose tissue 
through modulation of proliferation and differentiation of preadipocytes. Data by 
Ruzickova et al. indicates preadipocyte proliferation is inhibited in the adipose tissue of 
mice consuming n-3 fatty acids [241]. Differentiation of preadipocytes in rats and mice, 
are inhibited with the reduction in adipocyte derived PGI2 by n-3 fatty acid [219, 242]. 
Furthermore, n-3 fatty acids reduce differentiation by induction of apoptosis in post 
confluent preadipocytes, thereby lowering the preadipocyte pool [243].  
Along with the alteration of adipose tissue cellularity, n-3 fatty acids also 
decrease hypertrophy of mature adipocytes.  Adipose lipid filling is decreased in mice 
when 9 % of a high fat diet is replaced with EPA/DHA [234]. Similarly, obese mouse 
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models exhibit a decrease in adipocyte size with EPA supplementation [233, 241]. A 
reduction in adipocyte hypertrophy also occurs in the visceral adipose tissue of rats 
consuming EPA and DHA [244-246].  
Saturated Fatty Acid-Induced Inflammation 
Saturated fatty acids are capable of inducing inflammation and are the main 
constituents of the immunoreactive segment LPS called the lipid A component [247, 
248]. The SFAs; myristic, palmitic, and stearic acids are highly enriched in the lipid A 
component of LPS. Multiple groups have observed induction of an inflammatory 
response in adipose tissue with the individual SFAs of the lipid A tail [165, 249]. 
Induction of inflammation by SFA in adipose tissue has profound implications for dietary 
FA and the development of obesity.   
  Recent research has focused on the role of toll like receptors, specifically TLR4 
and TLR2, in inducing inflammation related to SFA [250-252].  Previous literature has 
narrowed in on TLR4 and TLR2 because of their distinct ability to bind LPS [251].  Data 
from our laboratory has shown a significant induction above control in NFκB and its gene 
product IL6 in 3T3L1 adipocytes treated with palmitate or LPS [253]. Furthermore, 
TLR4 null mice were protected from inflammation and insulin resistance when 
challenged with a high SFA diet [167, 254]. 
Saturated Fatty Acid –Associated Inflammation and Insulin Resistance 
High SFA content in cells results in high diacylglycerol and/or ceramide 
concentrations, both of which activate protein kinase C (PKC) [255, 256].  PKC activates 
 37 
IκB kinase and c-jun-N-terminal kinase, which, in turn, induce serine phosphorylation 
and inhibition of IRS-1. PKC also induces the production of pro-inflammatory cytokines 
[209].  
Saturated fatty acids increase TNFα, IL6, and MCP1 production through the 
activation of NFkB and AP1 transcription factors via the TLR4 and TLR2 signaling 
pathway [252, 257]. As described in a previous section, TNFα and IL6 are both involved 
in insulin resistance. The over accumulation of SFAs in tissue increases inflammation 
through the production of ROS and an increase ER stress caused by phosphorylation of 
eIF2α and  JNK [258]. Research also indicates that laurate, palmitate, and myristate 
increase the production of chemotactic proteins in adipose tissue, increasing the 
probability of macrophage infiltration [259]. The combined inflammatory induction, 
immune cell recruitment, and direct inhibition of insulin signaling by SFAs indicate a 
strong role for SFAs in obesity-related disease. 
Summary 
In the US, a staggering amount of economic, medical, and intellectual resources 
are devoted to the treatment of obesity and its co-morbidities.  Alleviation of obesity-
related lipotoxicity and inflammation would reduce the incidence of the obesity-
associated co-morbidities: insulin resistance and CVD.  Lipotoxicity is absent under 
normal metabolic conditions because adipose tissue sequesters excess lipid, preventing 
ectopic deposition. The plasticity of adipose tissue allows for rapid tissue expansion 
through hypertrophy and adipogenesis when under an increased demand for lipid storage.  
However, when the lipid load surpasses the limit of adipose tissue expansion, multiple 
 38 
stress signals develop.  Stressed adipose cells secrete inflammatory cytokines.  Paracrine 
cytokine activation of neighboring cells can lead to a cyclical inflammatory cascade. 
These pro-inflammatory cytokines cause the disruption of metabolic homeostasis in 
insulin-sensitive tissues like muscle and liver.  Furthermore, inflammation results in 
increased adipose tissue lipolysis. A lipolysis-mediated increase in circulating lipid can 
induce lipotoxicity and subsequent cyclic inflammatory, response metabolic 
dysregulation, and eventual tissue necrosis.  
The adipose tissue-derived protein adiponectin has anti-inflammatory, insulin-
sensitizing and adipogenic properties that can decrease the negative effects of adipose 
tissue stress.  However, the concentrations of this protein are negatively associated with 
the inflammatory milieu present in obesity. Previous literature indicates adiponectin 
reduces obesity-associated stress by promoting adipose tissue expansion.  High 
circulating concentrations of adiponectin in a leptin-deficient model of obesity results in 
massive adipose tissue accretion. Furthermore, the massive expansion of adipose tissue, 
mediated by adiponectin, protects against obesity associated inflammation and metabolic 
complications. The role of adiponectin in promotion of adipose tissue expansion 
represents a divergence from the previously published body of literature indicating that 
adiponectin promotes insulin sensitization through an increase in lipid oxidation and a 
decrease in glucose concentrations. Thus, further examination of the affects adiponectin 
has on adipose tissue morphology is warranted. There is currently no pharmaceutical 
treatment for low concentrations of adiponectin.  However, dietary fatty acids of the n-3 
family have been shown to increase adiponectin concentrations and decrease the 
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inflammation and metabolic disarray associated with obesity. It is unknown from these 
data if n-3 fatty acid consumption is required or if the endogenous conversion from 
precursor fatty acids is sufficient for the prevention of adipose tissue inflammation. 
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CHAPTER 3. METABOLIC AND INFLAMMATORY CHANGES IN 
ADIPOSE TISSUE OF PIGS FED DIETS HIGH IN LARD OR 
CANOLA OIL 
Abstract 
Low-grade inflammation associated with obesity is affected by multiple variables 
including dietary fatty acids. Previous literature has identified saturated fatty acids as an 
inducer of the pro-inflammatory cytokines TNFα and IL6 and the chemokine MCP1.  
Conversely, the omega 3 fatty acids, EPA and DHA, are associated with anti-
inflammatory effects.  There are limited data on the effects of EPAs precursor αLA.  The 
aim of this study was to characterize the inflammatory profile, tissue FA profiles, and 
metabolic state of swine after 11 weeks of consuming either a 30% canola oil diet, 25% 
lard diet, or control diet. We also sought to elucidate the role of dietary fatty acids in 
adiponectin production. Our data indicate no difference in serum inflammatory profile, 
metabolic profile, or adiponectin in swine after 11 weeks of diet. Furthermore, liver 
concentrations of EPA and docosapentaenoic acid (DPA) in liver were similar between 
the canola and control diets regardless of dietary fatty acid content. The pigs fed the 
canola diet had significantly lower numbers of subcutaneous adipose tissue macrophages 
compared to animals fed lard or control diets.  Overall, the data presented herein indicate 
dietary enrichment of canola oil reduces the inflammatory potential of the subcutaneous 
adipose tissue, whereas a diet rich in saturated fatty acids may take longer than 11 weeks 
for inflammation to occur in the commercial pig.  
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Introduction 
Obesity-associated inflammation and insulin resistance are among the most 
prevalent detriments to human health and well-being.  These chronic disease states 
impose enormous economic burdens on the U.S. and global economies. Consumption of 
diets high in saturated fat acids (SFA) are a major determinant of health, particularly with 
respect to cardiovascular disease, obesity, and insulin resistance (1, 2). The contribution 
of SFA to the development of disease is due to its biological activity, which extends far 
beyond that of a simple energy source.  The biological activity of SFA is exemplified by 
palmitate, which induces inflammation in cultured macrophages (3), dendritic cells (4), 
and 3T3-L1 adipocytes. Conversely, n-3 fatty acids stimulate adiponectin secretion from 
adipocytes, attenuate adipose expansion, and protect against inflammation in some 
models (5-14). Whereas n-6 polyunsaturated fatty acids (PUFA) have been reported as 
pro-inflammatory, the n-3 PUFAs attenuate inflammation through competition with n-6 
PUFA as a substrate for cyclooxygenase 2 and also via inhibition of the NFκB 
transcription factor (3, 15, 16). Consequently, there is considerable interest in enriching 
tissues with n-3 fatty acids via dietary means to alleviate inflammation.  
 The anti-inflammatory effects of n-3 PUFA are largely attributed to dietary 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) because the conversion 
from their precursor alpha-linolenic acid (αLA) is minimal in vivo (i.e., 6% or less of 
circulating DHA is from αLA) under normal dietary conditions (17). Recent evidence 
indicates that diets rich in αLA do, in fact, alleviate some types of inflammation and 
reduce the risk for cardiovascular disease (18, 19). Furthermore, Ren et al. (20) reported 
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that αLA attenuates the induction of NFkB and iNOS production in Raw 264.7 cells. It is 
relatively unknown, however whether αLA directly affects inflammation or if its 
byproducts EPA and DHA mediate the effects.  
 Rodent models have been the pillar of obesity and metabolic research, especially 
when invasive techniques are required. However, there are clear metabolic and 
physiological differences between humans and rodents, and these differences complicate 
the translation of biomedical research findings into effective dietary intervention 
strategies (21).  Consequently, alternative model species are being pursued, and the pig is 
emerging as an attractive biomedical model.  Contemporary genetic lines of pigs used in 
the commercial pork industry have been intensely selected for lean body composition 
over the past five decades.  However, these genotypes are an excellent humanoid model 
for atherosclerosis when fed substantial quantities of lard and cholesterol, and researchers 
have quite successfully extended this model to include atherosclerosis accelerated by 
streptozotocin-induced diabetes (22).  
 On the other hand, there is a paucity of data addressing obesity-linked 
inflammation in the adipose tissue of the pig or the impact of specific dietary fats on 
insulin resistance and inflammation. Our objective was thus two-fold.  First, we sought to 
determine whether inflammation could be induced in adipose tissue of commercial pigs 
fed a diet high in the saturated fatty acid palmitate from lard, and whether this 
inflammatory response differed from that induced by a diet high in αLA from canola oil.  
Secondly, we wanted to determine whether providing a diet high in α-LA resulted in a 
measurable enrichment of selected tissues with n-3 fatty acids. 
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Materials and Methods 
Animals and diets.  All animal procedures where approved by the Iowa State 
University Animal Care and Use committee. Twenty three, 18-week-old pigs of a 
Yorkshire cross commercial genotype averaging 63.6 kg were randomly assigned to three 
dietary treatments and housed in separate pens in an environmentally controlled facility.  
Water and feed were provided ad libitum for the duration of the 11-week study.  The 
dietary treatments consisted of a low fat, corn-based control, a high by saturated fat 
(Lard) diet and a diet high in canola oil (Table 1). The pigs were brought to a surgical 
plane of anesthesia with a mixture of ketamine, xylazine, and telazole (2.2mg/kg body 
weight of each component) following a 12 hour fast. After the animals were anesthetized, 
they were euthanized by exsanguination.  At the time of euthanasia, blood was collected 
from the jugular vein.  Samples of liver, longissimus dorsi (LD) muscle and subcutaneous 
and mesenteric adipose tissues were removed, frozen in liquid nitrogen, and stored at -
80° C until removed for sample analyses. 
Fatty acid analysis. All collected tissues were analyzed for fatty acid content by 
procedures as described previously by Gabler et al [23]. Briefly, lipids were extracted 
from 0.5 g of tissue using the method of Lepage and Roy. Following extraction, 0.74 µM 
heptadecanoic acid was added to each sample as a positive control.  Samples were then 
analyzed for fatty acid methyl esters using a gas chromatograph (model 6890; Hewlett-
Packard, Palo Alto, CA) with an Omegawax 320 capillary column (Sigma-Aldrich). 
RNA extraction and quantitative PCR . Total RNA was recovered from liver, 
muscle, and adipose tissue using Trizol reagent (Invitrogen, Carlsbad, CA), and residual 
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DNA was removed by DNase treatment (Turbo DNase, Ambion, Houston, TX, USA). 
The iScript cDNA synthesis kit (BioRad, Hercules, CA, USA) was used to reverse-
transcribe 2 µg of purified RNA. Primer sets were all designed for 60°C annealing 
temperature, allowing for the use of the same thermal cycling parameters: 95°C for 3 
min, followed by 40 cycles of 95°C for 15 s, 60°C for 30 s and 72°C for 30 s. Primer 
sequences for porcine SWC3, acetyl Co-A carboxylase (ACC), delta-6 desaturase, 
adiponectin, uncoupling protein 3 (UCP3), MCP1, 12S rRNA, and RPL32 genes are 
shown in Table 2.  The identity of the PCR products were confirmed by sequencing, 
cloned into the  pGEMT vector (Promega, Madison, WI), and diluted serially to provide a 
standard curve for each transcript. Reactions were carried out in an iCycler using the IQ 
SYBR Green Supermix kit (BioRad, Hercules, CA). Transcript abundance was calculated 
by regression against the standard curve for each gene, respectively, and expressed as log 
starting quantity using RPL32 as a co-variant via SAS. 
Immunofluorescence. Three-µm sections of subcutaneous adipose tissue adhered 
to cryo-glass slides were fixed in 100% ethanol, and kept at -80° C until 
immunofluorescence assays were performed.  Mounted tissue samples were hydrated by 
sequential immersion in 100% EtOH, 95% EtOH, 75% EtOH, and water.  Porcine 
myeloid cells where identified by anti-swine SWC3 antibody (VMRD, Pullman, WA) 
which was applied to the slides in buffer (pH 7.5) containing 10 mM NaPO4, 0.9% PBS, 
and 0.1%BSA at a dilution of 1:100 for 1.5 hours.  Secondary anti-mouse IgG conjugated 
to FITC (Abbiotec, San Diego, CA) was applied (1:1000) to the slides for 90 minutes. 
Slides were fixed in 10% formalin for 5 minutes and then mounted with non-drying 
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fluorescent  compatible Vecta Shield medium (Vector Laboratories, Burlingame, CA ) 
and visualized with a Zeiss light microscope with a Zeiss HRc Axiocam digital camera 
(Carl Zeiss, Thornwood, NY).  Adipocyte area, number, and myeloid cell number were 
measured at 20X magnification in the subcutaneous adipose tissue. Total SWC3 cells 
were divided by the total cell count to obtain the percentage of SWC3 positive cells.  All 
microscopy analysis were done using Axio Vision v4.5.0.0 (Carl Zeiss, Germany).   
Serum metabolites, cytokines, and hormones. IL6 was quantified via ELISA kit 
(R&D systems, Minneapolis, MN), Insulin and C-reactive protein were measured by an 
EIA from ALPCO diagnostics (Salem, NH).  All kits were used in accordance with the 
manufacturer’s protocol. Serum cholesterol (Roche, Indianapolis, IN), glucose (Roche, 
Indianapolis, IN), and NEFA (Randox, Crumlin, Co. Antrim, United Kingdom) were 
determined using an auto-analyzer (Roche, Indianapolis, IN) in the Department of 
Veterinary Pathology at Iowa State University. Serum adiponectin was arbitrarily 
quantified by Western blot. Briefly, the serum was diluted 15-fold and mixed with 2 X 
Laemmli buffer (Bio Rad, Hercules, CA). Samples were incubated at 100°C for 10 
minutes. After incubation samples were loaded onto 12% Mini-PROTEAN TGX gels 
(Bio Rad, Hercules, CA). Total protein was subjected to electrophoresis with a 25 mM 
Tris/ 192 mM Glycine/ 0.1% SDS buffer at 150 volts for 45 minutes, then transferred 
onto nitrocellulose membrane for chemiluminesecent detection using standard western 
blotting procedures. 
Statistical analyses. The mixed-model procedure in SAS (Version 9.1; SAS 
Institute, Cary, NC) was used to analyze all data. For gene transcription data, RPL32 was 
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used as a covariate. Data were randomized by pig for tissue analysis. All data were 
presented as least-squares means + standard error of the mean. Differences were 
considered significant at P<0.05 and trend towards significance at P<0.1. 
Results 
Diet and tissue fatty acid profiles. The fatty acid profiles of the diets and tissues 
are summarized in Tables 1 and 3.  As regards the saturated fatty acids, the major dietary 
differences were reflected in the proportion of palmitate (C16:0), which was similar in 
the control and lard diets, and approximately 50% lower in the canola oil diet.  Stearate 
(C18:0) was approximately 3-4 times higher in the lard diet vs. the control and canola oil 
diets.  Substantial differences were also noted for oleic acid (C18:1) with the canola oil 
diet containing approximately 2 and 1.5 times that of the control and lard diets, 
respectively. Linoleic acid (C18:2 n-6) was nearly 50% higher in the control diet vs. the 
lard and canola diets, and arachidonic acid (C20:4 n-6) was detected only in the control 
diet.  As expected, the canola oil diet contained the highest proportion of αLA (C18:3 n-
3), and EPA (C20:5 n-3) and docosapentaenoic acid (DPA, C22:5 n-3) were detected 
only in the control and canola oil diets, respectively. 
 Differential effects of diets on tissue fatty acid profiles were also readily apparent.  
Liver and both adipose depots from pigs fed the canola oil diet had appreciably lower 
proportions of palmitate vs. pigs fed the control and lard diets.  However, palmitate in the 
LD muscle was not influenced by diet.  Despite the dietary stearate being higher in the 
lard diet, the proportion of this fatty acid was reduced in liver by the canola oil diet. 
Stearate enrichment in the adipose depots were highest in the control pigs, followed by 
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the groups fed the lard and canola oil in order.  Stearate and oleic acid enrichment in LD 
muscle were not affected by diet. However, oleic acid was higher in all other tissues of 
the pigs fed the canola oil diet.  Linoleic acid was slightly enriched in the liver of pigs fed 
the canola oil diet.  Arachidonic acid was not detected in either adipose depot, but the 
lard diet increased the concentration of this fatty acid in the liver by 42% vs. the control 
diet, whereas the canola oil diet reduced it by 23%. With the exception of the 
subcutaneous adipose depot, the canola oil diet increased concentrations of αLA 
substantially across tissues.  Neither EPA nor DPA were detected in adipose tissue or LD 
muscle; in liver, the proportions of both fatty acids were lower in the pigs fed the lard diet 
than either the control or canola oil diet.  
Body weight and subcutaneous adipocyte size. Final body weights and adipocyte size 
data are presented in Figure 2 A and B.  Despite the high fat and metabolizable energy 
content of the lard and canola diets, pigs fed these diets were not heavier than controls.  
The p-value for the difference between the canola diet and lard diet adipocyte size was p 
= 0.057, but neither diet resulted in a difference vs. the control diet. 
Serum metabolites, insulin and inflammatory markers. As shown in Table 4, total 
cholesterol was significantly greater (p< 0.05) in pigs fed the lard diet relative to the other 
two groups, and although diet did not influence LDL concentrations, HDL concentrations 
were increased (p<0.05) in pigs fed the lard diet compared to the control group.  Serum 
concentrations of glucose, insulin, NEFA and triglycerides were not influenced by either 
high fat diet, nor were the inflammatory markers, IL6 or C-reactive protein. Serum 
adiponectin concentrations were not different between treatments (data not shown). 
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Adipose myeloid cell infiltration and inflammation markers. The number of cells 
positive for the porcine myeloid marker, SWC3, in subcutaneous adipose tissue was 
significantly lower (p<0.05) in pigs fed the canola oil diet than in either the control or 
lard group (Figure 3A).  However, this result was not confirmed by SWC3 mRNA 
expression (Figure 3B). Likewise, MCP1 expression (Figure 2C) was not altered by 
either high fat diet. Adiponectin transcript abundance was higher in the subcutaneous 
adipose tissue versus mesenteric adipose tissue irrespective of diet (Figure 4A). 
Adiponectin transcript was not influenced by diet in either subcutaneous or mesenteric 
adipose tissue depots.  
Metabolic and mitochondrial responses. Irrespective of diet, acetyl Co-A carboxylase 
(ACC) expression was the lowest in the liver and greatest in the subcutaneous adipose 
tissue (Figure 5B). Acetyl Co-A carboxylase expression was not influenced by diet in the 
liver or mesenteric adipose tissue, but there was a trend for a reduction in expression with 
the canola diet in the subcutaneous depot. Subcutaneous adipose tissue was identified as 
having the greatest abundance of ACC and the liver as the lowest, mesenteric adipose 
tissue was excluded in the investigation of desaturase transcript abundance. As shown in 
Figure 4A, Δ-6 desaturase was expressed similarly in liver and subcutaneous adipose 
tissue and diet did not alter transcript abundance. The expression of mitochondrial 
specific 12S rRNA , a proxy measure for mitochondrial density, was not responsive to 
diet in the liver, LD muscle, or subcutaneous adipose tissue, while the lard diet 
significantly reduced 12S rRNA in mesenteric adipose vs. the control and canola oil diets 
(Table 4D). Expression of UCP-3 in LD muscle (Figure 4B), the primary location of this 
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protein, was increased in pigs fed the lard diet relative to both the control and canola oil 
diets 
Discussion 
We report herein a significant enrichment of EPA in the liver of swine fed a diet 
enriched with canola oil and negligible in concentrations of EPA or DHA. The liver fatty 
acid profile of the pigs fed the control diet, which had low amounts of EPA and DHA 
from fish meal, were similar to the canola fed pigs.  One of the main enzymes involved in 
the conversion of αLA to EPA is delta 6 desaturase. The mRNA concentration of delta 6 
desaturase was unchanged with diet, but was greater in the liver compared to adipose 
tissue. We expected to see an increase in the expression of delta 6 desaturase in the 
tissues of pigs fed the canola diet based on previous data indicating n-3 fatty acids 
increase PPARα activation (23) and subsequently increase delta 6 desaturase activity 
(24). Previous literature also indicates n-3 fatty acids mediate a decrease in the transcript 
abundance of  genes involved in de novo lipogenesis (25). ACC transcript was observed 
in the subcutaneous depot of animals fed the canola diet.  We observed a significant 
decrease in ACC transcript abundance in the subcutaneous adipose tissue of animals 
consuming the canola diet compared to the lard or control fed animals.  In line with 
previous literature we report greater ACC transcript abundance in subcutaneous adipose 
tissue compared to the liver regardless of diet (26). Based on transcript abundance only, 
these data indicate SQ adipose tissue is the primary location for de novo lipogenesis, 
while fatty acid desaturation is most likely to occur in the liver of swine.   
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Previous literature indicates dietary fatty acids can increase electron transport 
chain uncoupling by increasing the concentration of uncoupling proteins in multiple 
tissues (27, 28).  Uncoupling protein 3 (UCP3) gene transcript was measured to 
determine if addition of n-3 fatty acids in the diet increased UCP3 abundance. The UCP3 
transcript abundance of the longissimus dorsi was significantly greater in the animals 
consuming the lard diet compared to the other two diets. This was unexpected based on 
previous data that indicates rats fed diets enriched with 40% fish oil exhibit an almost 
two-fold increase in UCP3 expression in muscle tissue versus a control diet (29).  
Furthermore, Bassaganya-Riera et al. (30) indicates dietary supplementation with fish oil 
in an inflammatory bowel disease pig model significantly increased UCP3 mRNA 
expression in colonic tissue  compared to animals fed a control diet.(30). A third study 
reported an induction of UCP3 expression with unsaturated fatty acids supplement  and to 
a lesser extent with palmitate supplementation (28).  A possible explanation for the lack 
of n-3 mediated increase in UCP3 is that our n-3 diet consisted of αLA and not EPA and 
DHA rich fish oil used in previous studies.  
Previous work by Flachs et al. indicates mitochondrial density increases in 
adipose tissue of mice consuming a diet supplemented with n-3 fatty acids (31).  We 
assessed mitochondrial density in the muscle, liver, subcutaneous and mesenteric   
adipose tissues. Our approach was to examine mitochondrial number through transcript 
abundance of the mitochondrial specific 12S rRNA. We report a significant reduction of 
12S rRNA in the mesenteric adipose tissue of animals fed the lard diet compared to the 
control or canola diets.  When the 12S rRNA data and the UCP3 data are interpreted 
together it indicates that the lard diet increases energy dissipation as heat and 
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subsequently decreases mitochondrial density. Further research is needed to identify how 
the lard diet reduced the mitochondrial density in mesenteric adipose tissue and the 
possible role of UCP3. 
Our laboratory as well as others have previously shown an inflammatory response 
with high SFA diets in mice (32, 33).  In the current study, we did not identify a 
significant difference in serum concentrations of the pro-inflammatory cytokines IL6, 
CRP and MCP1 or the anti-inflammatory protein adiponectin with any of the diets. Since 
previous literature indicates adiponectin expression is up-regulated by n-3 fatty acids, we 
sought to measure adiponectin transcript abundance in adipose tissue (34).   Adiponectin 
transcript abundance in adipose tissue was not affected by diet, but was significantly 
greater in the SQ adipose depot compared to the MES adipose depot.  
Immunofluorescent visualization of myeloid cell infiltration into SQ adipose 
tissue identified significantly fewer positive cells in the tissue of canola diet fed animals 
versus the control or lard fed animals. Given the lack of inflammatory, chemotactic, or 
anti-inflammatory signals, we and others postulate that the reduction in myeloid cells is a 
direct outcome of the dietary fatty acids incorporation into this tissue. Previous literature 
reported that OA and EPA interfered with the interactions  between immune cells and the 
adhesion molecule ICAM-1 (35). Furthermore, αLA supplementation in humans caused a 
decrease in the soluble adhesion molecules sVCAM-1 and sE-selectin in the absence of a 
change in serum inflammatory profile (36).  Interestingly, the subcutaneous adipose 
tissue of the canola fed animals had significantly greater enrichment of OA and αLA than 
the other diets.  Based on previous literature, it is inferred that adipose tissue enrichment 
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of OA and αLA mediated a decrease in immune cell adhesion leading to reduced adipose 
tissue infiltration.  
According to previous literature, adipocyte size is reduced with n-3 fatty acid 
supplementation (37). Although not significant, our data indicates a trend (P<0.1) for a 
reduction in SQ adipocyte area in animals fed the canola diet versus the lard diet. A 
reduction of adipocyte size with n-3 fatty acid enrichment has been previously attributed 
to the induction of oxidation and/or decreased preadipocyte differentiation and increased 
preadipocyte proliferation (31).  Regardless of the mechanism behind the reduction in 
adipocyte size, smaller adipocytes are not associated with inflammation and thus are 
more desirable. 
In conclusion, we report data herein indicating that αLA is converted to EPA in 
the liver of pigs fed a diet enriched with canola oil at concentrations equal to a diet 
containing fish meal. Furthermore, the abundance of ACC and delta 6 desaturase in liver 
and adipose tissue suggests these tissues are responsible for fatty acid conversion and 
lipogenesis, respectively. Our identification of no difference in serum inflammation, a 
lower accumulation of adipose tissue immune cells, and a trend for small SQ adipocytes 
in pigs fed the canola diet indicates these animals had a low risk of developing lipid 
induced insulin resistance. Our data also indicates that the lard diet was not sufficient in 
generating systemic inflammation within the short duration of 11 weeks, but did result in 
greater UCP3 transcription in muscle. It is possible that this genetic line of pig is 
predisposed to SFA induced activation of energy dissipation through electron transport 
uncoupling and not through adipocyte storage, thus protecting it from the adverse effects 
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of SFA. From our data, it is apparent that a longer feeding duration is needed to fully 
elucidate the effects of αLA and SFA in the pig.  
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 SFA  MUFA  Omega 6  Omega 3 
Diet  C16:0  C18:0  
 C18:1  
(OA) 
 C18:2 n6 
(LA)  
C18:3n6 
(γLA)  
C20:4n6 
(ARA)  
 C18:3n3 
(αLA)  
C20:5n3 
 (EPA) 
C22:5n3 
(DPA)  
  g/100g 
Control  20.1  4.2   22.5   38.7  n.d.
1
  0.3   2.7  0.9  0.6  
Lard  19.4  14.3   32.9   24.8  n.d. 
1 
n.d. 
1 
 2.3  n.d.
1
  n.d.
1
  
Canola  9.1  3.3   49.0   26.6  n.d. 
1 
n.d.
1
   8.1  n.d.
1
  0.18  
Table 1. Fatty acid profiles of swine diets  
 79 
 
Gene Forward Reverse 
RPL32  
TGGAAGAGACGTTGTGAGCAA  CGGAAGTTTCTGGTACACAATGTAA  
ACC  TGTTGTCATGGTCACACCCGAAGA  TTGTTGTTGTTTGGTCCTCCTGGC   
SWC3  TCCTTGACAACTCCGACAACTGGA ACCTTGTAGAAGACGTGGAGCCTT  
MCP 1  AGTCACCAGCAGCAAGTGTCCTAA TCAGGCTTCAAGGCTTCGGAGTTT 
 
 
Δ6 Desaturase  ACTTAAAGGGTGCCTCTGCCAACT AAGTGGTGCAGAAGAACCAGCCTT   
Adiponectin  CGTGATGGCAGAGATGGCGT CCACACTGAATGCTGAACGG 
UCP 3  ACGATGGATGCCTACAGGAC  TCCGAAGGCAGAGACAAAGT  
12S RNA  AAACTCAAAGGACTTGGCGGTGCT TAGGGTTTGCTGAAGATGGCGGTA 
 
Table 2. Swine PCR primers 
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 SFA  MUFA  Omega 6  Omega 3 
Tissue  Diet C16:0  C18:0   
C18:1  
(OA) 
 C18:2 n6  
(LA) 
C18:3n6  
(γLA) 
C20:4n6  
(ARA) 
 C18:3n3 
(αLA)  
C20:5n3 
(EPA)  
C22:5n3  
(DPA) 
  
g/100g 
Liver  Control  16.41+1.52
a
  28.20+0.79
a
   13.27+1.00
a
   14.86+1.67
a
  0.03+0.08
a
  14.15+0.87
a
  0.07+0.18
a
  3.36+0.48
a
  3.08+0.32
a
  
Liver  Lard  13.21+1.44
a
  28.72+0.75
a
   15.62+0.93
a
   16.90+1.58
a
  0.18+0.08
ab
  18.57+0.82
b
  0.24+0.17
a
  0.22+0.46
b
  0.94+0.30
b
  
Liver  Canola  7.42+1.42
b
  23.75+0.74
b
   23.22+0.92
b
   22.00+1.56
b
  0.30+0.08
b
  10.92+0.81
c
  1.99+0.17
b
  2.74+0.45
a
  2.24+0.30
a
  
LD  Control  22.18+0.40
a
  14.17+0.58
a
   31.56+2.32
a
   21.69+1.64
a
  n.d. 
1 
7.15+0.81
ab
   n.d. 
1 
n.d. 
1 
n.d. 
1
 
LD  Lard  20.64+0.38
a
  14.17+0.54
a
   30.18+2.19
a
   23.58+1.55
ab
  n.d. 
1 
9.67+0.76
b
   n.d. 
1 n.d. 
1
 n.d. 
1
 
LD  Canola  16.99+0.37
b
  12.39+0.54
b
   33.99+2.16
a
   27.01+1.53
b
  n.d. 
1 
6.05+0.75
a
   1.96+0.37b  n.d. 
1
 n.d. 
1
 
Mes.  Control  26.89+1.83
a
  19.66+0.55
a
   34.34+0.78
a
   12.13+0.94
a
  1.81+0.29
a
  n.d. 
1 
 0.39+0.12
a
  n.d. 
1
 n.d. 
1
 
Mes.  Lard  23.70+1.73
a
  15.27+0.52
b
   38.14+0.74
a
   13.10+0.89
a
  3.72+ 0.27
b
  n.d. 
1 
 0.57+0.12
a
  n.d. 
1
 n.d. 
1
 
Mes.  Canola  12.53+1.71
b
  10.16+0.52
c
   43.23+0.73
b
   16.11+0.88
b
  4.60+0.27
c
  n.d. 
1 
 4.38+0.12
b
  n.d. 
1
 n.d. 
1
 
SubQ  Control  20.49+0.95
a
  12.15+0.48
a
   37.05+1.06
a
   18.64+1.15
a
  5.78+0.64
a
  n.d. 
1
  0.66+0.42
a
  n.d. 
1
 n.d. 
1
 
SubQ  Lard  17.98+0.90
a
  9.68+0.45
b
   39.98+1.00
a
   20.59+1.08
a
   5.89+0.60
ab
  n.d. 
1
  0.65+0.40
a
  n.d. 
1
 n.d. 
1
 
SubQ  Canola  8.89+0.89
b
  5.21+0.45
c
   48.77+0.99
b
   23.74+1.07
b
  6.76+0.59
b
  n.d. 
1
  1.38+0.39
a
  n.d. 
1
 n.d. 
1
 
Table 3. Fatty acid profiles of porcine tissues following 11 weeks of diet 
Different letters signify a P< 0.05 
1
n.d. represents a non-detectable concentration 
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 Control  Lard  Canola Oil  
Total Cholesterol (mg/dl)  97.31 + 5.3
a
  116.14 + 5.3
b
  94.61 + 5.1
a
  
LDL (mg/dl)  50.58 + 9.6  73.56 + 8.4  56.19 + 9.2  
HDL (mg/dl)  61.53 + 5.4
a
  82.68 + 4.7
b
  73.48 + 5.1
ab 
 
NEFA (mg/dl)  0.18 + 0.1  0.26 + 0.1  0.22 + 0.1  
Triglycerides (mg/dl)  40.43 + 7.0  33.38 + 6.1  37.96 + 6.7  
Glucose (mg/dl)  124.8 + 19.8  121.03 + 17.3  130.56 + 18.8  
Insulin (ug/ml)  0.09 + 0.02  0.04 + 0.02  0.06 + 0.03  
C-Reactive protein (ng/ml)  25.94 + 3.1  20.0 + 2.8  24.40 + 3.9  
IL6 (pg/ml)  45.37 + 7.7  54.86 + 6.7  46.89 + 7.3  
 
  
Different letters signify P< 0.05 
Table 4. Serum inflammation and metabolic profile of swine following 11 weeks of diet 
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Figure 2. Body weight or adipocyte size were not altered by diets 
All measurements were reported after 11 weeks of diet in Control 
(n=7) pigs, Lard (n=8) pigs, and Canola Oil (n=8) pigs. A) Final 
body weight of pigs separated by diet B) Average area of 
subcutaneous adipocytes.  
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Canola Lard Control 
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Figure 3. Infiltration rate of myeloid immune 
cells and transcript abundance of chemotactic 
protein in subcutaneous adipose tissue  
Measurements were performed on tissue 
collected at the completion of the 11-week diet 
treatment. A) Immunofluorescence of myeloid 
immune cells visualized at 20 X magnification in 
subcutaneous adipose tissue B) Transcript 
abundance of the myeloid specific marker SWC3 
in subcutaneous adipose tissue C) Transcript 
abundance of MCP1 in subcutaneous adipose 
tissue.  Different letters indicate P< 0.05.  
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Figure 4. Adipose tissue expression of adiponectin 
is depot specific. Transcript abundance of UCP3 
in LD muscle was influenced by diet. 
Measurements were obtained from tissue procured 
after 11 weeks of diet. A) Transcript abundance of 
adiponectin in the mesenteric and subcutaneous 
adipose tissue depots of all animals regardless of 
diet B) UCP3 transcript abundance in the LD 
muscle separated by diet.  Different letters signify 
P< 0.05. 
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Figure 5. Acetyl-CoA Carboxylase and delta 6 desaturase enzyme abundance. Tissue 
and diet-dependent alterations in mitochondrial specific gene transcript. 
All gene expression measurements were obtained from 1 g of tissue harvested from 
animals at completion of 11-week diet. Tissues consist of: liver, mesenteric adipose 
tissue (MES), subcutaneous adipose tissue (SubQ), and longissimus dorsi muscle 
(LD).  A) Transcript abundance of delta 6 desaturase in liver or subcutaneous tissues 
B) Acetyl-CoA carboxylase transcript abundance in lipogenic tissue C) Tissue-
specific mitochondrial specific transcript abundance regardless of diet D) Transcript 
abundance of mitochondrial specific 12S rRNA in subcutaneous adipose tissue by 
diet. Different letters signify P< 0.05.   
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CHAPTER 4: ADIPONECTIN NULL MICE FED A HIGH FAT DIET HAVE 
UNALTERED BODY COMPOSITION AND METABOLIC PROFILE  
Abstract 
Obesity is associated with reduced expression and circulating concentrations of 
adiponectin and low grade inflammation in adipose tissue, which contributes to the onset 
and progression of insulin resistance. Previous studies using adiponectin-deficient mice 
have shown conflicting results as regards to the development of insulin resistance and 
change in body weight in response to high fat diets. The aim of this study was to quantify 
changes in body fat and protein content in relation to the adiponectin wild type (ADN
+/+
), 
heterozygous (ADN
-/+
) and knockout (ADN
-/-
) genotypes fed normal low fat vs. high fat 
diets.  We also sought to determine whether inflammation was influenced by adiponectin 
genotype. Groups of male and female mice from each genotype were fed a high fat or 
low fat diet for 16 weeks. Our data indicate that adiponectin genotype did not influence 
total carcass fat and protein content, even in mice fed the high fat diet.  However, 
adipocyte size (area) was increased and adipocyte number decreased in ADN
-/-
 females 
fed the high fat diet, perhaps indicative of a unique role for adiponectin in high fat diet 
induced adipogenesis in females. Neither serum concentrations of CRP or macrophage 
infiltration in adipose tissue were altered by diet, sex, or genotype. Collectively, these 
results indicate that adiponectin deficiency does not alter body fat or protein accretion, 
nor does it exacerbate inflammation associated with diet induced obesity.   
Introduction 
Adiponectin is produced largely by adipocytes and is linked to the regulation of 
energy metabolism, insulin sensitivity and inflammation (see [1,2] for detailed reviews). 
Early work with recombinant protein indicated that adiponectin not only promotes 
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postprandial triglyceride clearance from the blood, but also stimulates fatty acid oxidation 
in skeletal muscle and cultured myocytes [3,4]. Collectively, these actions seemed to 
explain in part the suppression of adipose expansion in mice fed a high-fat obesigenic 
diet and treated with adiponectin [3,5], and to explain adiponectin mediated 
improvements in insulin function in models of obesity and insulin resistance [6,7]. 
However, more recent findings have implicated adiponectin as a metabolic signal which 
stimulates adipogenic pathways fundamental to adipose expansion. Overexpressing the 
high molecular weight form of adiponectin in mice lacking leptin resulted in marked 
expansion of the subcutaneous adipose depot and simultaneously corrected the metabolic 
disturbances associated with the morbid obesity and the accompanying inflammation and 
insulin resistance [8]. Although several studies [9-12] have evaluated the effect of 
adiponectin on body weight or the size of specific fat pads, direct determinations of total 
lipid and protein mass have not been reported in relation to adiponectin status, nor has 
there been a direct assessment of adipocyte size. The primary objective of the study 
reported herein was to determine whether adiponectin status influences body composition 
or markers of inflammation in mice fed a high fat diet. 
Materials and Methods 
Animals.  Adiponectin-null mice were generated by removal of exon 2 of the 
adiponectin sequence on chromosome 16. Founder adiponectin null (ADN 
-/-
 )mice were 
back crossed onto the original C57BL/6J wild type strain, and ADN 
+/-
 breeding pairs 
were established to produce ADN 
-/-
, ADN 
+/-
, and ADN 
+/+
genotypes. Genotypes of 
offspring were determined using DNA extracted from tail tissue. The PCR was 
performed using a three primer set (Forward1: 
5’
CTTTACGGTATCGCCGCTC
3’
, 
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Forward2: 
5’
CAACTAAGACACTGATGA
3’
, Reverse: 
5’
CTTTACGGTATCGCCGCTC
3’
). PCR products were separated by electrophoresis and 
detected with SYBR Safe reagent (Invitrogen, Carlsbad, CA). Wild type primers 
produced a product size of 250 kb, whereas the adiponectin product was 550 kb. At six 
weeks of age (+/- 1 week) mice where placed onto experimental diets in blocks of 8-12 
mice with all three genotypes represented. A total of 139 mice (68 females and 71 males) 
were used. The diets consisted of a low-fat chow control and an obesisgenic diet high in 
monounsaturated fatty acids (Table3).  
Body composition.  After 16 weeks on experimental diets, mice were euthanized 
by CO2 asphyxiation. Blood was quickly collected via cardiac puncture and serum was 
stored at -80C prior to analysis. Gonadal fat pads, defined as the fat pad adjacent to 
uterine horns in females and next to epididymis in males, were excised, weighed, frozen 
in liquid nitrogen, and stored at -80°C. Whole carcasses (less the blood and fat pad) were 
autoclaved for 45 min at 250°C in a volume of water equal to one half the carcass 
weights. After autoclaving, carcasses were homogenized in a blender and the homogenate 
freeze dried for 48 hours. The dried homogenate was reground in the blender under liquid 
nitrogen, and sub-sampled for fat and protein determinations via ether extraction and the 
Kjeldahl procedure, respectively as previously described [13,14]. A subset of gonadal fat 
pads were homogenized in lysis buffer A (50mM Tris·Hcl pH 7.5, 1mM EDTA, 1mM 
DTT, 10% glycerol, 1% Triton X-100, 50mM Sodium fluoride, 5mM sodium 
pyrophosphate, 0.1mM PMSF, 5mg/ml aprotinin, 5mg/ml leupeptin, and 5mg/ml 
pepstatin A ) for protein recovery. The protein was quantified by the BCA assay (Pierce, 
Rockford, IL). Fat pad protein averaged less than 3% of total fat pad weight. 
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Consequently, fat pad weights were multiplied by the correction factor and included in 
the calculation of total fat percentage.  
Immunohistochemstry.  Sections of gonadal fat pad were fixed overnight in 10% 
buffered formalin pH 6.8 and imbedded in paraffin. Thereafter, sections of 3 µm 
thickness were mounted onto microscope slides for morphometry and macrophage 
determinations. Immunohistochemstry was performed as previously described to identify 
macrophages in the tissue [15]. Briefly, an anti-F4/80 antibody and ABC Kit (Vector 
Labs, Burlingame, CA) were used to detect macrophages. Thereafter, the sections were 
counter-stained in eosin and hematoxylin. Adipocyte size (µm
2
), adipocyte number, and 
macrophage number were acquired by visualization with a Zeiss light microscope at 20X 
magnification in four different fields and averaged. 
Serum analyses.  Glucose, total cholesterol and triglycerides were measured using 
an auto analyzer at the pathology lab at Iowa State University. ELISA or EIA were used 
to quantify adiponectin and IL6 (R & D Systems, Minneapolis, MN) C-reactive Protein 
and insulin (Alpco Diagnostics, Salem, NH). 
Statistics. The mixed-model procedure in SAS (Version 9.1; SAS Institute, Cary, 
NC) was used to analyze all data. A blocked study design was used with blocks 
corresponding to the dates for each group of mice started on dietary treatments, therefore 
diet, sex, and genotype are treated as fixed variables. All data are presented as least-
squares means + standard error of the mean. Differences were considered significant at 
P≤0.05 and trend towards significance were noted at P≤0.10. Mean separations were 
performed by the pdiff procedure when a significant interaction of main effects was 
identified. Serum adiponectin concentrations were analyzed without the ADN -/- given their 
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lack of measurable concentrations. Thus the genotype variable for the serum adiponectin 
concentrations consisted of the ADN +/- and the ADN +/+ mice only. 
Results 
Adiponectin concentrations. Final serum adiponectin concentrations are presented 
in Figure 6. As expected, mice with the heterozygous genotype had adiponectin 
concentrations at approximately 40% (genotype effect, P<0.0001) of those in the ADN 
+/+
 
group, and females had higher concentrations (sex effect, P <0.0001) than males. 
However, the sex by diet and genotype by sex interactions were significant (P = 0.006 
and 0.03, respectively). These interactions resulted from the ADN 
+/+
 females having 
significantly higher adiponectin concentrations (P = 0.05) than all other groups, and the 
high fat diet reduced serum adiponectin only in the ADN 
+/+
 females. 
Serum inflammation and metabolic parameters.  Interleukin 6 (IL6) was largely 
undetectable in the serum, with no indication of sex, diet or genotype being a contributing 
factor. Consequently, inflammatory status was assessed by measuring serum C-reactive 
protein (CRP). Neither dietary treatment, gender nor genotype significantly altered serum 
CRP concentrations (Table 5), and interactions of main effects were not significant.  
The metabolic state of the mice was assessed based on serum concentrations of 
glucose, insulin, cholesterol, and triglycerides (Table 5). Mice fed the high fat diet had 
lower glucose concentrations than those fed the control diet (diet effect, P = 0.002), and 
females had lower concentrations than males (sex effect, P < 0.0002). However, the 
significant genotype by sex interaction (genotype by sex, P = 0.02) indicated that the 
higher concentration of glucose in males and lower concentration in females did not 
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occur in the ADN 
+/+
 mice. There was a significant three-way interaction (sex by diet by 
genotype, P = 0.04) for serum insulin concentrations; although wild-type males and all 
females were unresponsive to diet, the insulin concentrations increased appreciably 
(P<0.0001) in ADN 
+/-
 males fed the low fat diet, male ADN 
+/-
 and ADN 
-/- both had 
higher concentrations (male vs. female with in genotype, P<0.0001) than females of the 
same genotype, irrespective of diet. Cholesterol concentrations were greater in males (sex 
effect, P = 0.0001). Serum triglyceride concentrations were not significantly influenced 
by genotype or sex, but mice fed the high fat diet had lower concentrations (diet effect, P 
= 0.01). 
Body composition. Body composition and caloric intake data are presented in Table 6. 
Final body weights were greater in mice fed the high fat diet (diet effect, P = 0.001). 
However, the significant sex by diet interaction (sex by diet, P = 0.03) indicates that 
females were more responsive to the high fat diet than males, with the exception of the 
female ADN 
-/- mice (sex by diet by genotype, P = 0.009). In terms of actual weight gain 
over the experimental period, males gained more weight (sex effect, P = 0.0007). A 
significant sex by diet interaction (sex by diet, P = 0.04) indicates the females on the low 
fat diet gained less than the other groups. Body fat (percentage basis and actual mass) 
was lower in mice fed the high fat diet (diet effect, P =0.02), and this was especially 
apparent in the males (sex by diet, P = 0.05). Additionally, males had higher percentages 
of protein and higher actual protein mass (sex effect, P ≤ 0.01). There was also a trend 
(sex by diet, P = 0.08) for a sex by diet interaction which reflects the lower protein mass 
in the females on the high fat diet.  
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Immunohistochemistry (IHC) and adipocyte number.  The gonadal fat pads where 
excised for IHC and determinations of adipocyte size and number. Female ADN 
-/- mice 
responded to the high fat diet by significantly increasing adipocyte area (P=0.02) and 
decreasing the adipocyte number (P=0.008) (Figure 7). The ADN 
+/-
 females did not 
differ from ADN 
-/-
 or ADN 
+/+
 female mice. In the males, adipocyte morphology was not 
affected by diet or genotype. Although macrophages were identified in the adipose tissue 
of all mice, macrophage infiltration was not influenced by diet, sex or genotype, nor were 
there significant interactions of main effects (Figure 8).  
Discussion 
The effects of adiponectin genotype (i.e., ADN 
-/-
, ADN 
+/-
 and ADN 
+/+
) on 
circulating adiponectin concentrations have been reported by multiple groups [9-12]. We 
confirmed an absence of serum adiponectin (i.e., undetectable concentrations) in the 
homozygous knockout mice, whereas the ADN 
+/-
 mice had measurable, but substantially 
lower serum concentrations than the wild type (ADN 
+/+
) mice. Consequently, our model 
allowed us to evaluate the effects of adiponectin status on the response to the high fat diet 
at distinct concentration differences ranging from undetectable to normal wild type 
concentrations. 
In addition to genotype, serum adiponectin concentrations were also influenced by 
sex. Females had higher adiponectin concentrations than males, and ADN 
+/+
 females fed 
the high fat diet exhibited a decrease in adiponectin. This sexual dimorphism and the 
reduction in adiponectin caused by the high fat diet (females only) has also been 
documented by Gui et al. [16] and Bullen et al. [17], respectively. Furthermore, the lack 
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of a dietary response in our male mice is consistent with the report by Barnea et al. [18] 
which indicated no reduction in serum adiponectin concentrations in male mice fed a 
high fat diet for 20 weeks. Collectively, these findings indicate a unique susceptibility of 
females vs. males to the suppressive effects of a high fat diet on circulating adiponectin. 
However, the underlying mechanism for the sexual dimorphic response in serum 
adiponectin concentrations with high fat diet has not been identified. 
The data presented herein support the findings of several groups that adiponectin null 
mice are not different than wild type mice in terms of body weight [9-12]. Moreover, our 
results show clearly that the absence of adiponectin does not affect total fat or protein 
content on an absolute mass or percentage basis. We also report that a high fat diet 
consistently promotes an increase in final body weight within genotype, and that this 
response is more pronounced in the females. Although there were not significant 
genotype differences observed in body composition measures, the data clearly indicate 
distinct gender differences. Specifically, as compared with males, the female mice were 
less likely to have a change in percent fat or protein when fed the high fat diet. 
Interestingly, in the absence of differences in overall body composition, the female ADN
-
/-
 mice had larger, but fewer, gonadal adipocytes. Adipose tissue composed of larger, but 
fewer, adipocytes suggest that adipogenesis may be diminished in adiponectin-deficient 
females. This finding is intriguing in light of the recent finding that over expressing 
adiponectin in the leptin deficient obese mouse stimulates expansion of subcutaneous 
adipose tissue [8].  Surprisingly, the male ADN
-/-
 mice did not show adipocyte 
hypertrophy.  Whether the lack of adipocyte hypertrophy  relates directly to male sex 
hormones remains to be determined.    
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Given  implicated role of adiponectin as a local and systemic anti-inflammatory 
factor [13,14], it was pivotal to investigate inflammatory status in this model. Clinical 
investigations have identified an increase in serum IL6 and CRP in patients with the 
metabolic syndrome, which commonly presents with low adiponectin concentrations 
[19,20]. Ouchi et al. [21] reported an inverse correlation between serum adiponectin and 
serum CRP concentrations in humans and an increase in mouse CRP mRNA transcript 
abundance in adipose tissue of adiponectin knockout animals. Based on these findings, 
we expected an increase in serum IL6 and CRP in the ADN
-/-
 mice, especially those fed 
the high fat diet. However, IL6 was largely undetectable in the serum of our mice, and 
whereas CRP was readily measurable, adiponectin genotype did not influence CRP 
concentrations, regardless of sex or diet. These data indicate that the absence of 
adiponectin does not necessarily predispose mice to a chronic inflammatory state, even 
when fed a high fat diet. The fact that macrophage infiltration was not altered by 
genotype, irrespective of diet, further substantiates the lack of differences in the 
inflammatory status of adipose tissue in these mice.   
Adiponectin is a known moderator of insulin sensitivity, but reports on insulin 
sensitivity in adiponectin null mice are conflicting [9-12]. The fasting glucose and insulin 
concentrations of the mice used in this study seemed high as compared with previous 
reports. The explanation for this difference is not readily apparent, but it is possible that 
the difference relates to the shorter duration of fasting that we used vs. that described in 
other reports (6 hours vs. 12-16 hours) [9-11,18]. However, relative to the present study, 
the glucose concentrations were influenced by genotype, although a genotype by sex 
interaction was indicated in that glucose concentrations were higher in wild type females 
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fed the low fat diet. We also found higher serum insulin concentrations in the ADN 
+/-
 
male mice on the low fat diet. Perhaps most important, our collective glucose and insulin 
data to not indicate that the absence of adiponectin, or the low circulating concentrations 
in the ADN
+/-
 mice, is sufficient to predispose mice to the insulin resistance associated 
with high fat diets. Albeit, we cannot rule out the possibility that the type of fat fed in the 
high fat diet (i.e. unsaturated vs. saturated fats) may impact this outcome. Although the 
overall effect of the high fat diet was not as expected, the fact that male mice exhibited 
differences in insulin concentrations while females did not, further highlight the 
importance of sex in the interpretation of results obtained in studies comparing genetic 
lines and(or) dietary factors.  
In summary, our findings indicate that adiponectin deficiency alone does not 
predispose mice to chronic inflammation associated with a diet high in unsaturated fat, 
nor does it cause significant changes in the accretion of protein or fat in mice fed normal 
low fat or obesigenic high fat diets.  However, the female-specific adipocyte hypertrophy 
and corresponding reduction in adipocyte number in ADN
-/-
 mice fed the high fat diet 
support a possible unique role for adiponectin in adipogenesis in females. 
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Figure 6. Serum adiponectin in heterozygote and wild type mice after 16 weeks of diet. 
Main effects of sex and genotype were significant (12.3 + 0.5 vs. 8 + 0.5 µg/ml 
for females vs. males, P<0.0001) and (5.8 + 0.5 vs. 14.6 + 0.5 µg/ml for ADN
+/-
 
vs. ADN
+/+
 P=0.03) as well as the sex*diet and genotype*sex two-way 
interactions (P=0.006 and P= 0.03 respectively). Main effects of diet exhibited a 
trend (P=0.08) while genotype*diet two-way interaction and the three-way 
interaction were not significant (P=0.16). Mean + SEM. Different letters signify P 
< 0.05 
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Table 5.  Serum Metabolic and Inflammatory Markers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Significant effect of diet (227.8 + 7.7 vs. 261.3 + 8.1 for HF vs. LF diet, P=0.002); Significant  
sex effect (225.1 + 8.2 vs. 264.0 + 7.6 for females vs. males, P= 0.0002); Significant  genotype*sex interaction, P= 0.02) 
2
Significant effect of sex (0.73 + 0.25 vs. 1.75 + 0.18 for females vs. males, P<0.0001); Trend  
for sex*diet  interaction (P=0.08)  and significant genotype*sex effect (P=0.057); 
Significant effect of genotype*diet (P=0.017) and significant genotype*sex*diet effect (P=0.04) 
3
Significant effect of sex (128.1 + 15.2 vs. 206.3 + 14.7 for females vs. males, P<0.0001); Trend  
for effect of diet (178.2 + 15.4  vs.156.2 + 14.7 for HF vs. LF diet, P=0.07) 
4
Significant effect of diet (108.7 + 6.1 vs. 131.4 + 6.4 for HF vs. LF diet, P= 0.01)  
 
Genotype  Sex  Diet  
Glucose 
(mg/dl)
1 
 
Insulin 
(ng/ml)
2 
 
Total 
Cholesterol  
(mg/dl)
3 
 
Triglycerides 
(mg/dl)
4 
 
C-Reactive 
Protein 
(ng/ml)  
ADN
+/-
  F HF  206.8 + 17.5
ab 
 0.71 + 0.36
a 
 142.6 + 24.6
a 
 83.7 + 16.7
a 
 29.6 + 2.7
a 
 
ADN
+/-
  F LF  233.7 + 17.5
abcd 
 0.7 1+ 0.31
a 
 116.6 + 20.9
a 
 112.5 + 10.0
ab 
 29.2 + 2.5
a 
 
ADN
-/-
  F HF  199.3 + 17.4
a 
 0.69 + 0.31
a 
 132.0 + 25.0
a 
 86.3 + 13.9
a 
 29.4 + 2.4
a 
 
ADN
-/-
  F LF  217.5 + 18.4
abc 
 0.55 + 0.31
a 
 105.1 + 21.4
a 
 122.7 + 11.9
ab 
 28.0 + 2.5
a 
 
ADN
+/+
  F HF  208.1 + 17.4
ab 
 0.87 + 0.31
a 
 133.6 + 24.6
ab 
 134.7 + 13.7
b 
 29.7 + 2.3
a 
 
ADN
+/+
  F  LF  285.0 + 23.2
e 
 0.84 + 0.36
a 
 139.0 + 33.2
ab 
 140.0 + 23.7
b 
 31.3 + 2.7
a 
 
ADN
+/-
  M  HF  278.5 + 17.4
de 
 1.09 + 0.31
a 
 224.9 + 21.4
c 
 112.2 + 10.7
ab 
 30.4 + 2.4
a 
 
ADN
+/-
  M LF  284.9 + 16.5
e 
 3.05 + 0.33
c 
 203.5 + 21.5
bc 
 134.9 + 12.0
b 
 29.6 + 2.5
a 
 
ADN
-/-
  M HF  249.4+ 17.5
cde 
 2.20 + 0.33
b 
 231.7 + 21.8
c 
 117.1 + 10.9
ab 
 33.5 + 2.7
a 
 
ADN
-/-
  M LF  284.0 + 17.4
e 
 1.66 + 0.46
ab 
 188.2 + 20.3
bc 
 139.4 + 16.7
b 
 26.5 + 3.9
a 
 
ADN
+/+
  M HF  224.6 + 17.4
abc 
 1.01 + 0.36
a 
 205.0 + 27.6
c 
 118.3 + 13.7
ab 
 32.8 + 2.6
a 
 
ADN
+/+
  M LF  262.7 + 15.8
cde 
 1.44 + 0.33
ab 
 185.1 + 9.3
bc 
 139.0 + 9.7
b 
 29.1 + 2.5
a 
 
  
1
0
0
 
Table  6.  Body Composition, Gain and Energy Intake  
 
1
Significant effect of diet (38.3 + 0.8 vs. 35.5 + 0.8 for HF vs. LF diet, P=0.001); Significant  
sex*diet  interaction (P=0.03); Trend for genotype*sex*diet interaction (P=0.09) 
2.
Significant effect of diet (30.5 + 2.2 vs. 35.51 + 2.3 for HF vs. LF diet, P=0.02); Significant  
sex*diet  interaction (P=0.05) 
3
Significant sex*diet interaction (P=0.01) 
4
Significant effect of sex (14.3 + 0.4 vs. 16.1 + 0.4 for females vs. males, P=0.01); Trend for  
sex*diet  interaction (P=0.08) 
5
Significant effect of sex (5.1 + 0.2 vs. 5.9 + 0.2 for females vs. males, P=0.0002) 
6
Significant effect of sex (14.7 + 0.9 vs. 17.5 + 0.9 for females vs. males, P=0.0007); Trend for  
sex *diet  interaction (P=0.08) 
7
Significant effect of sex (2.56 + 0.02 vs. 2.50 + 0.02 for females vs. males, P<0.0001);  
Significant diet effect (2.42 + 0.02 vs. 2.64 + 0.02 for HF vs. LF diet, P<0.0001) 
 
Genotype  Sex  Diet  
FBW  
(g)
1 
 
Total Fat  
(%) 
2 
 
Total Fat  
(g)
3 
 
Total 
Protein 
(%)
4 
 
Total 
Protein (g)
5 
 
Total 
 Gain (g)
6 
 
Energy Intake 
(kcal/wk)
7 
 
ADN+/-  F  HF  39.1 + 1.5
a
  30.5 + 4.4
ab
  11.8 + 2.0
ab
  14.3 + 0.9
ab
  5.2 + 0.3
ab
  17.6 + 1.5
de
  95.7 + 0.4
c
    
ADN+/-  F  LF  34.2 + 1.6
b
  33.0 + 4.0
ab
  11.9 + 1.9
ab
  14.9 + 0.8
ab
  5.1 + 0.3
a
  12.7 + 1.6
ab
  119.2 + 0.3
e
    
ADN
-/-
  F HF  37.0 + 1.6
ab 
 31.0 + 4.1
ab 
 11.9 + 1.9
ab 
 13.5 + 0.9
ab 
 5.0 + 0.3
a 
 15.1 + 1.5
abcd 
 93.4 + 0.4
c 
   
ADN
-/-
  F LF  34.5 + 1.6
b 
 35.4 + 3.9
ab 
 12.1 + 1.8
ab 
 14.9 + 0.8
ab 
 5.0 + 0.3
a 
 12.9 +1.6
abc 
  115.0 + 0.3
de 
   
ADN
+/+
  F HF  39.5 + 1.6
a 
 39.2 + 3.7
b 
 16.1 + 1.8
b 
 12.9 + 0.8
a 
 5.2 + 0.2
ab 
 18.1 + 1.6
de 
  92.7 + 0.4
c 
   
ADN
+/+
  F LF  33.2 + 1.6
b 
 35.2 + 4.5
b 
 12.7 + 2.1
ab 
 15.2 + 1.0
ab 
 5.2 + 0.3
ab 
 11.5 + 1.6
a 
 112.9 + 0.3
de 
   
ADN
+/-
  M HF  38.2 + 1.5
ab 
 25.4 + 4.1
a 
 10.2 + 1.9
a 
 15.9 + 0.9
b 
 5.9 + 0.3
b 
 18.0 + 1.5
de 
  82.8 + 0.4
a 
   
ADN
+/-
  M LF  36.1 + 1.6
ab 
 38.5 + 4.3
b 
 15.2 + 2.0
ab 
 16.5 + 0.9
b 
 6.0 + 0.3
b 
 16.2 + 1.5
bcd 
  100.0 + 0.3
d 
   
ADN
-/-
  M HF  39.7 + 1.6
a 
 30.5 + 4.2
ab 
 12.1 + 2.0
ab 
 15.7 + 0.9
b 
 5.9 + 0.3
b 
 20.1 + 1.5
e 
  90.2 + 0.4
a 
   
ADN
-/-
  M LF  36.9 + 1.6
ab 
 35.2 + 4.5
b 
 13.7 + 2.1
ab 
 16.1 + 1.0
b 
 5.9 + 0.3
b 
 16.8 + 1.6
cde 
  91.5 + 0.3
b 
   
ADN
+/+
  M  HF  36.1 + 1.5
ab 
 26.4 + 4.4
a 
 9.6 + 2.0
a 
 17.1 + 1.0
b 
 6.0 + 0.3
b 
 16.1 + 1.5
bcd 
  82.6 + 0.4
a 
   
ADN
+/+
  M LF  38.2 + 1.5
a 
 35.8 + 3.7
b 
 13.9 + 1.8
ab 
 15.6 + 0.8
b 
 6.0 +  0.2
b 
 17.5 + 1.5
de 
 102.7 + 0.3
d 
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Figure 7. Mean adipocyte area from gonadal fat pads after mice were fed experimental 
diet for 16 weeks. Main effects of sex, diet, genotype were not significant (P= 
0.20), nor were two-way or three-way interactions significant (P= 0.17). Mean + 
SEM.  
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Figure 8. Immunohistochemstry of gonadal fat pad excised after 16 weeks of diet. A)  
Percentage of F4/80 positive cells in fat pad. Mean + SEM. B) Representative 
picture of an ADN
-/-
 female on a high fat diet. C) Representative picture of an 
ADN
-/-
 female on low fat diet 
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CHAPTER 5. ADIPONECTIN SUPPRESSES THE PROLIFERATION 
AND DIFFERENTIATION OF STROMAL VASCULAR CELLS 
DERIVED FROM ob/ob MICE. 
Abstract 
Adiponectin has been suggested to protect against metabolic dysfunction in 
leptin-deficient (ob/ob) obese mice by increasing adipose tissue expansion. The goal of 
our work was to investigate the role of adiponectin in proliferation and differentiation of 
stromal vascular cells (SVC) recovered from subcutaneous adipose tissue of ob/ob and 
wild type (WT) mice in an in vitro system. Cells were grown until 5 days post 
differentiation. The cell culture media were supplemented with or without adiponectin 
and leptin. Proliferation of SVC was examined after 18 hr of culture. We identified a 
greater basal rates of proliferation in and lower rates of differentiation in WT cells 
compared to  the ob/ob cells. The WT cells were more proliferative whereas the ob/ob 
cells had greater differentiation rates.  Adiponectin decreased the transcript abundance of 
the differentiation-associated transcription factors CEBPα and PPARγ in the ob/ob SVC 
by 1 and 2 fold respectively.  Furthermore, adiponectin decreased the proliferation of 
ob/ob cells compared with media control. Overall, we report different growth patterns for 
WT and ob/ob SVC cells and that adiponectin decreases the differentiation and 
proliferation of ob/ob SVC cells.  
Introduction 
Excessive expansion of adipose tissue during obesity increases proinflammatory 
cytokine secretion and suppresses the anti-inflammatory, insulin-sensitizing hormone 
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adiponectin [1-3].  Previous literature indicates that inflammation and insulin resistance 
can be suppressed when adiponectin concentrations are restored to normal [4, 5]. 
Suppression of inflammation by adiponectin occurs through inhibition of the nuclear 
factor kappa B transcription factor (NFκB) or through direct inhibition of TNFα signaling 
[6, 7]. Reduction of insulin resistance by adiponectin is the result of increased β-
oxidation and/or the direct interaction of AMP-activated protein kinase (AMPK) with 
insulin receptor agonists  [8]. These physiological effects of adiponectin were the 
accepted dogma until 2007. 
In 2007, Kim et al. published a manuscript suggesting adiponectin overexpression 
in the leptin-deficient ob/ob obese mouse model protects against obesity-related insulin 
resistance and inflammation through expansion of subcutaneous adipose tissue [9]. An 
increase in circulating native adiponectin concentrations comparable to PPARγ agonist 
treatment was achieved by transgenic overexpression of a mutated form of adiponectin. 
This mutated adiponectin was not detected in the serum, indicating it was retained by 
adipocytes while promoting the secretion of native adiponectin. It is unknown if this 
mutated adiponectin has a role in the regulation of adipose tissue growth. Furthermore, 
the physiological implications of leptin deficiency were ignored in this study [9].  
To adequately examine the effects of high adiponectin concentrations on 
preadipocytes, we investigated the role of exogenous adiponectin in the absence of 
intracellular adiponectin retention. My study was designed to identify the role of 
adiponectin in the proliferation and differentiation of stromal vascular cells isolated from 
the subcutaneous adipose tissue of ob/ob mice. Based on the work of Kim et al. [9], we 
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hypothesized that adiponectin treatment would increase proliferation and differentiation 
of preadipocytes in the SVC fraction of ob/ob adipose tissue.  
Materials and Methods 
Stromal vascular cell isolation. Six week old ob/ob and C57BLK/6J mice were 
procured from Jackson Laboratories (JAX).  Six ob/ob mice and ten C57BLK/6J mice 
were euthanized via CO2 asphyxiation and inguinal subcutaneous adipose tissues were 
collected in 37°C PBS with 3% penicillin/streptomycin (SP) mix. All of the tissue within 
each genotype was pooled together to create one cell lot. Adipose tissue was digested for 
40 minutes at 37°C, mixed at 150 oscillations per minute (opm) in low glucose DMEM 
containing 1mg/ml collagenase ( Worthington Biochemical, Lakewood, NJ) and 1% SP.  
After digestion, samples were centrifuged at 1000 X g for 8 minutes. After centrifugation 
the supernatant and adipocytes were decanted.  The SVC pellet was resuspended in 5 ml 
of red blood cell lysis buffer (0.154 M NH4Cl, 10mM KHCO3,0.1mM EDTA, with a pH 
of 7.3) for 10 minutes and then spun at 1000 X g for 8 minutes. Supernatant was decanted 
and the pellet was resuspended in low glucose DMEM containing 10% fetal bovine 
serum (FBS) and 2% SP. Following re-suspension the cells were incubated in 12 well 
plates and 75 cm
2
 flasks. Cells were grown in 5% CO2 at 37°C for all experiments. Media 
were changed at 2 hours post plate and again at 24 hours post-plating.   At 48 hours post 
plating, the cells were washed with PBS and trypsinized to break up densely populated 
clusters.  After trypsinization, the cells were thoroughly mixed by gentle pipetting and 
diluted 1:1 in low glucose media containing 10% FBS and 1% SP and allowed to re-
adhere to culture plate.  
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Differentiation cell culture. Three days after the cells were re-plated, confluence 
was 85% as based on visual identification via microscopy. Media were changed to 
differentiation media consisting of low glucose (1,000 mg/L) DMEM (Sigma Aldrich, St. 
Louis, MO, USA), 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA) 1% 
penicillin/streptomycin (SP) mix, 1.7 µM insulin, 1.0 µM dexamethasone, 1.5 mM 
isobutylmethylxanthine, and 0.4 mM biotin.  The differentiation media were then treated 
with or without either 20 µg/ml recombinant mouse adiponectin (BioVendor, Candler, 
NC, USA), 10 ng/ml recombinant mouse leptin (R and D Systems, Minneapolis, MN, 
USA), or the combination of adiponectin and leptin at respective concentrations.  Cells 
were incubated for 72 hours at which time the media were changed to low glucose 
DMEM containing 10% FBS, 1% SP, insulin, and adiponectin or leptin.  The treatment 
was ended 48 hours after the second media change, 5 day post differentiation, at which 
time media and cells harvested and mRNA and protein were collected for G3PDH or 
PCR assays. All treatments were replicated 9 times for analysis of PPARγ and C/EBPα 
transcript abundance, and 3 times for G3PDH. 
Proliferation cell culture. Cells were plated at 2,000 cells per well in a 96-well 
culture plates and incubated overnight.  The following day the media were changed to 
basal media containing BrdU with either 20 ug/ml adiponectin or 10 ng/ml leptin 
treatments. Cells were incubated for 18 hours and at completion were processed 
according to the ELISA manufacturers protocol (Millipore, Billerica, MA, USA). Each 
treatment was repeated 5 times across 3 plates. 
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G3PDH assay. At 5 days, post differentiation media was removed and the cells 
were washed with an isotonic phosphate buffer. Lysis buffer (0.25 M sucrose, 1mM 
Na2EDTAH2O, 5 mM tris base, 1 m M dithiothreitol, pH to 7.4) was added to each well 
and cells were scraped and transferred to tubes on ice.  Cells were mechanically lysed by 
repeated passage through a needle and syringe. Lysate was spun at 12,500 X g for 5 
minutes at 4°C.  Supernatant was removed to new tubes on ice and 0.15 ml of supernatant 
was then transferred to a cuvette. Addition of 0.1 ml substrate buffer (0.71 mg/ml 
dihydroxyacetone phosphate lithium in H2O) and 0.8 ml of assay buffer  (200 mM 
triethanolamine, 5 mM Na2EDTAH20, 1/10 final volume β-mercaptoethanol, 20 µM 
NADH) were added immediately prior to measurement of absorbance.  Absorbance was 
measured every 2 seconds for 3 minutes at 340nm. The total protein concentrations of the 
supernatants were identified using the protocol for a BCA reagent kit (Pierce, Rockford, 
IL, USA). The change in optical density was used to calculate the activity of G3PDH per 
minute and was corrected for total protein. 
mRNA Extraction and Quantitative Real Time PCR. Recovery of total RNA was 
performed as described by the Trizol reagent (Invitrogen, Carlsbad, CA, USA) protocol.  
Residual DNA was removed with DNase treatment according to manufactures protocol 
(Turbo DNase, Ambion, Houston, TX, USA). Reverse transcription of 2 µg of purified 
RNA was performed using a iScript cDNA synthesis kit (BioRad, Hercules, CA, USA). 
All primers were designed for use with the following thermal cycler parameters: 95°C for 
3 min, followed by 40 cycles of 95 °C for 15s, 60°C for 30s, and 72°C for 30s.  The 
primer sequences for GAPDH, PPARγ and CEBPα are reported in Table 7. Serial 
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dilutions of sequence confirmed gene target clones (pGEMT vector, Promega, Madison, 
WI, USA) were used to generate a standard curve for each transcript. Quantitative real 
time PCR reactions were performed on an iCycler using IQ SYBR Green Supermix 
(BioRad, Hercules, CA, USA).  Regression analysis of the standard curve was used to 
calculate the transcript abundance, expressed as log starting quantity. GAPDH was used 
as the housekeeper control gene. 
Statistical Analysis. All data were analyzed using the mixed-model procedure in 
SAS (Version 9.0; SAS Institute, Cary, NC, USA). GAPDH transcript abundance was 
used as a covariate for the gene transcription data. Treatments were randomly assigned 
and represented once per cell culture plate. The fixed effects consisted of plate, treatment, 
and genotype. All data are presented as least-square means + standard error of the mean. 
Differences were considered significant at P<0.05 and trends toward significance were 
reported at P< 0.1.  Differences among means were determined by the pdiff procedure 
when a significant interaction was identified for treatment, genotype, or treatment by 
genotype. 
Results 
Media adiponectin and leptin. The concentrations of adiponectin and leptin in 
media are reported in Figures 9 and 10.  Concentrations of both proteins were dependent 
on the supplementation status of each treatment. Media from leptin treatments had 
concentrations of approximately 10 ng/ml while non-supplemented media had less than 2 
ng/ml.  Interestingly, the media from the WT cells receiving leptin supplementation had 
greater concentrations of leptin compared with all other treatments. Adiponectin 
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concentrations in the media were also treatment dependent with values of 10 µg/ml and 1 
µg/ml for adiponectin supplementation and control media respectively. 
Proliferation. Cellular proliferation is reported in Figure 11 as concentration of 
cellular incorporation of BrdU reagent. The WT cells receiving the control, adiponectin, 
or leptin media had significantly greater concentrations of BrdU compared to the 
combined adiponectin/leptin treatment or any of the ob/ob cells. BrdU concentrations of 
the ob/ob cells were unchanged with leptin or adiponectin/leptin supplementation. 
However, treatment of ob/ob cells with adiponectin alone resulted in significantly lower ( 
p< 0.05) BrdU incorporation compared to the other treatments. 
G3PDH enzyme activity. The enzyme activity of G3PDH is reported in Figure 12 
and was significantly greater in the cells from ob/ob animals. Treatment of ob/ob cells 
with leptin, whether alone or in conjunction with adiponectin, significantly reduced 
G3PDH activity. In the WT cells, G3PDH enzymatic activity was not significantly 
different between treatments.   
Gene expression markers of differentiation. PPARγ and CEBPα transcript 
abundance are summarized in Figures 13 and 14 respectively. PPARγ transcript 
abundance was greater (p= 0.0001) in all of the ob/ob treatments compared to WT cells. 
The PPARγ transcript of ob/ob cells treated with the combined adiponectin/leptin 
treatment were lower than the control or leptin treatment (p=0.007 and p= 0.036 
respectively). Likewise, the adiponectin treatment in ob/ob cells resulted in a trend for 
reduced (p=0.067) PPARγ transcript compared to the control.  CEBPα abundance was 
greater (p=0.0001) in ob/ob cells compared to WT cells regardless of treatment.  
  
110 
Adiponectin treatment reduced CEBPα transcript 1.7 fold compared to control in the 
ob/ob cells. The WT cells treated with adiponectin, leptin or the combination of both 
exhibited a 2 fold decrease in CEBPα compared to the control. 
Discussion 
We report herein significant phenotypic differences in differentiation and 
proliferation of subcutaneous SVCs obtained from leptin deficient ob/ob and wild type 
mice.  Cells from WT animals were highly proliferative while ob/ob cells were prone to 
differentiation. Furthermore, our data indicates a significant difference in the 
responsiveness of ob/ob SVC cells and WT cells to adiponectin and leptin treatment.  
Treatment of ob/ob SVCs with leptin, whether alone or with adiponectin, reduced 
differentiation compared to control as measured by G3PDH. This finding is supported by 
Thomas et al. who showed a significant decrease in adipocyte differentiation of human 
stromal bone marrow treated with leptin [10]. It appears from our data that adiponectin 
does not influence adipocyte differentiation as assessed by G3PDH assay. Contrary to 
these findings, previous literature indicates adiponectin increases the differentiation of 
human preadipocytes as confirmed by microscopy [11].  
It is possible that genetic markers of differentiation are present prior to protein 
expression of G3PDH. The gene expression profile of adipocyte differentiation is well 
characterized and consists of two distinct phases of transcription factor abundance [12-
18]. Early in the differentiation process there is an increase in the transcription factors 
CEBPβ and CEBPδ [17, 19]. These two transcription factors mediate the production of 
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CEBPα, which accompanies PPARγ as a late phase transcription factor [14]. Previous 
literature indicates that the early phase differentiation signals CEBPβ and CEBPδ are 
increased by STAT3. STAT3 is a transcription factor that associates with the JAK/STAT 
family of receptors, which includes the leptin receptor [20]. Leptin receptor signaling can 
also increase the activation of two inhibitors of adipocyte differentiation, ERK and 
AMPK [21]. Our data showed no change in CEBPα or PPARγ with leptin treatment in 
either cell type.  However, the co-treatment of leptin and adiponectin decreased PPARγ 
transcript abundance in the ob/ob cell line compared to media control. The treatment of 
cells with adiponectin alone reduced the transcript abundance of PPARγ and CEBPα in 
ob/ob SVCs compared to vehicle control. Based on these data it appears that adiponectin 
is the driving force in the reduction of PPARγ observed in our co-treatment experiment.  
Multiple signaling proteins associated with adiponectin are involved in the 
regulation of CEBPα/β/δ and PPARγ. For instance, adiponectin has been shown to inhibit 
STAT3 via activation of JNK in hepatocytes [22]; if this occurs in preadipocytes, the 
inhibition of early phase transcription factors could occur. Furthermore, activation of 
AMPK by adiponectin decreases the expression of PPARγ and CEBPα in mesenchymal 
cells [23]. Previous reports using AICAR to activate AMPK show a significant reduction 
in PPARγ and CEBPα in preadipocytes [24, 25].  Likewise, the absence of AMPK in 
mice results in adipose tissue expansion, characterized by hypertrophy and differentiation 
[26]. Interestingly, the ob/ob SVCs in our study present with a similar phenotype as the 
adipose tissue of AMPK KO mice. These data indicate that the greater differentiation rate 
observed in our ob/ob SVCs may be mediated by lower basal AMPK concentrations. 
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Given that adiponectin is a strong inducer of AMPK [8, 27] and that AMPK inhibits 
differentiation transcription factors, it is likely that the inhibition of adipocyte 
differentiation by adiponectin in our study is mediated through AMPK.   
Previous literature indicates leptin suppresses proliferation of 3T3L1 
preadipocytes [28, 29]. Likewise, adiponectin has been implicated as an antagonist of key 
growth factors and thus inhibiting proliferation of multiple cell types [30]. We report a 
lower basal proliferentiation rate of ob/ob subcutaneous SVC cells compared to wild type 
control cells. Our data indicates leptin does not affect SVC proliferation. Furthermore, we 
observed a significant decrease in the proliferation of ob/ob cells with adiponectin 
treatment. The proliferation of WT cells remained unchanged with leptin and adiponectin 
treatments. However, WT proliferation was significantly decreased from control with the 
co-treatment of adiponectin and leptin. This data suggests the combined activation of the 
adiponectin and leptin pathways, most likely AMPK, results in a decrease in WT cell 
proliferation. These data contribute to our developing hypothesis that ob/ob cells have 
lower basal AMPK activity and therefore are more sensitive to its affects. If our 
hypothesis is correct, greater AMPK activation would be required to suppress WT cell 
proliferation as compared to the ob/ob cells.   
In summary, we report a decrease in ob/ob SVC differentiation associated 
transcription factors and a reduction in proliferation with recombinant adiponectin 
treatment. Examination of our data has lead to the formation of a new hypothesis that 
ob/ob cells are physiologically more sensitive to the effects of active AMPK than WT 
mice. This hypersensitivity to AMPK explains, at least in part, the phenotypic differences 
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in differentiation and proliferentiation observed between the WT and ob/ob cells in this 
study. Based on our findings, it is evident that further investigations into the role of 
AMPK concentrations in ob/ob subcutaneous SVCs are warranted. 
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Figure 9. Adiponectin concentration in the media at 5 days post differentiation. SVC 
derived from ob/ob or WT mouse subcutaneous adipose tissue were cultured with or 
without 20 µg/ml adiponectin and/or 10 ng/ml leptin in standard differentiation media 
for 5 days. Different letters identify P < 0.05. Mean + SEM  
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Figure 10. Leptin concentrations in the media at 5 days post differentiation. SVC 
derived from ob/ob or WT mouse subcutaneous adipose tissue were cultured with or 
without 20 µg/ml adiponectin and/or 10 ng/ml leptin in standard differentiation media 
for 5 days. Different letters identify P < 0.05. Mean + SEM  
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Figure 11. Differences in proliferation of stromal vascular cells.  Incorporation 
of BrdU into newly formed cells was assessed in SVC derived from ob/ob or 
WT mice.  Cells were cultured for18 hours in media treated with or without 20 
µg/ml adiponectin and/or 10 ng/ml leptin. Different letters identify P<0.05. 
Mean + SEM. 
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Figure 12. Differences in differentiation assayed by 
G3PDH activity. G3PDH activity in stromal vascular cells 
obtained from wild type or ob/ob mice and cultured for 5 
days post differentiation. Culture media were treated with 
or without 20 µg/ml adiponectin and/or 10 ng/ml leptin. 
Different letters identify P< 0.05. Mean + SEM. 
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Figure 13. Transcript abundance of the late phase 
differentiation specific gene PPARγ. Transcript abundance of 
PPARγ from stromal vascular cells derived from ob/ob or wild 
type mice at 5 days post differentiation. Cells were treated with 
or without 20 µg/ml adiponectin and/or 10 ng/ml leptin. 
Different letters indicate P< 0.05. Mean + SEM 
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Figure 14.  Differences in mRNA markers of 
differentiation. Transcript abundance of CEBPα from 
stromal vascular cells at 5 days post differentiation 
cultured in media treated with or without 20µg/ml 
adiponectin and/or 10 ng/ml leptin. Different letters 
signify P< 0.05. *P = 0.067. Mean + SEM. 
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Gene Forward Reverse 
Pref-1 AGA AAG GCC AGT ACG AAT GCT CCT
 
TTG CGG CTA CGA TCT CAC AGA AGT
 
CEBPα AGA AGT CGG TGG ACA AGA ACA GCA GCG TTG TTT GGC TTT ATC TCG GCT
 
PPARγ ACA TAA AGT CCT TCC CGC TGA CCA AAA TTC GGA TGG CCA CCT CTT TGC 
 
Table 7. Realtime PCR Primer Sequences 
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CHAPTER 6. GENERAL CONCLUSIONS 
We demonstrated that adiponectin transcript abundance and serum concentrations 
in swine are not altered with the consumption of large amounts of αLA or SFA. However, 
this study led to the identification of significant liver enrichment with EPA and DPA, 
indicating in vivo conversion of αLA in swine fed canola oil. Interestingly, liver tissue 
had greater transcript abundance of delta 6 desaturase compared to adipose tissue, which 
had higher ACC transcript. These findings support previous literature that has identified 
adipose tissue of swine as the main location of de novo lipogenesis [1]. However, the 
identification of a higher potential for desaturation in the liver compared to adipose tissue 
is not represented in the literature. Given the similar concentrations of EPA and DPA in 
only the liver of the control and canola diets, it is difficult to form a conclusion on 
physiological relevance. It appears that the fatty acid enrichment in the liver of these diets 
is basally regulated, given the similar fatty acid profiles even though the canola diet had 
an overabundance of substrate. We also identified significantly less myeloid cell 
infiltration in the subcutaneous adipose tissue of pigs fed the canola diet compared with 
control, which was accompanied by a trend for smaller adipocytes in this group. It is not 
completely apparent whether the reduction of myeloid cell number is a result of αLA 
supported mechanisms or through oleic acid mediated reduction in adhesion molecules as 
seen in previous literature [2]. Together, these results indicate that a diet high in canola 
oil reduces the inflammatory potential of adipose tissue by reducing macrophage 
infiltration and increasing adipocyte number. The use of a production pig line that has 
been selected for leanness over many generations and a dietary period that was not long 
enough to induce obesity may have precluded the observation of a dietary alteration in 
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adiponectin or inflammation.  Therefore, it would be of interest to examine the effect of 
these diets in an obesity-prone pig line like the Ossabaw pig.  An obese pig model would 
have a more pronounced difference in inflammation and adiponectin concentrations 
allowing for a better examination of dietary effects.  
To further elucidate the effects of high fat diets on adiponectin function, 
specifically its role in body composition, we utilized an adiponectin null murine model 
was used.  The mice had varying serum adiponectin ranging from non-detectable to wild 
type concentrations, based on their genotype: adiponectin null homozygotes, adiponectin 
null heterozygotes, and adiponectin wild type mice. Adiponectin null mouse models have 
been utilized for the examination of inflammation and metabolism in the absence of 
adiponectin. A controversial finding in adiponectin null mice is the development of 
insulin resistance with a high fat diet but no change in body weight from wild type 
control animals [3-6]. Therefore, we sought to investigate body composition differences 
between the adiponectin-null mice and wild type animals.  To determine the effect of a 
lack of adiponectin on body composition, we fed adiponectin null and wild type mice 
high fat diets.  We reported no significant difference between wild type or adiponectin 
null mice for body composition, metabolic profile, or inflammatory status. Interestingly, 
we identified significantly greater adipocyte size and lower total adipocyte numbers in 
adiponectin null female mice. Conversely, previous literature has reported a significant 
increase in adipocyte number in the adipose tissue of adiponectin-transgenic mice with 
high serum adiponectin concentrations [7].  These findings imply adiponectin has a direct 
influence on adipocyte size and number.  
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To determine whether adiponectin regulates preadipocyte differentiation and 
proliferation, we treated mouse stromal vascular cells with recombinant adiponectin. In 
order to align our work with previous reports, we chose to use SVC from obese ob/ob 
leptin-deficient and non-obese wild type mice. To account for the leptin deficiency in 
ob/ob cells, we added a positive control treatment that consisted of leptin-supplemented 
media. We identified a significant reduction in proliferation and differentiation of 
adiponectin treated ob/ob cells. Adiponectin treatment of wild type cells did not alter 
proliferation or differentiation, but the combined leptin adiponectin treatment 
significantly lowered proliferation.  Furthermore, we identified a significant difference 
between wild type and ob/ob cells in basal proliferation and differentiation rates.  Cells 
from wild type mice were more proliferative while ob/ob cells were more adept at 
differentiating.  These data indicate that in the leptin-deficient animal high concentrations 
of adiponectin inhibit the expansion of subcutaneous adipose tissue.  
It is unknown what molecular mechanisms are controlling inhibition of 
proliferation and differentiation by adiponectin and why only in leptin-deficient cells. 
Given the identification of a suppression in wild type SVC proliferation with the 
combined leptin and adiponectin treatment, the first logical step in this investigation of 
molecular mechanisms would be AMPK. Previous literature indicates AMPK activation 
in preadipocytes reduces the transcript abundance of the late phase differentiation factors 
PPARγ and C/EBPα [8, 9]. Likewise, the lack of leptin- mediated AMPK activation in 
ob/ob cells may predispose them to a higher sensitivity for AMPK activation. The use of 
the AMPK agonist 5-Aminoimidazole-4-carboxyamide ribonucleoside (AICAR) in ob/ob 
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cell culture would further elucidate the role of AMPK in the inhibition of proliferation 
and differentiation in this cell line. Furthermore, to fully investigate the role of 
adiponectin in adipose tissue expansion, it is essential to determine its relationship with 
leptin.  Investigation of adiponectin in a leptin-resistant model such as the db/db mouse 
would further elucidate this relationship and directly relate to the leptin-resistance seen in 
obese humans. Moreover, further work is needed to determine if high concentrations of 
adiponectin are needed to mediate the desired adipose tissue effects or if restoration of 
normal concentrations in obese animals is sufficient. 
Collectively, our data provides evidence that high concentrations of adiponectin 
influence the adipocyte population of adipose tissue. However, it seems that the potency 
of adiponectin as a determinant of preadipocytes proliferation or differentiation is 
dependent on the genetic background of the cells. Furthermore, we show no change in 
body composition in the absence of adiponectin, indicating the modulation of adipocyte 
growth by adiponectin reflects a pharmacological, rather than physiological, mechanism. 
In the absence of a dietary change in adiponectin in the pig, we identified tissue 
enrichment of essential fatty acids and a significant reduction in myeloid cells. A 
decrease in myeloid cell accumulation in adipose tissue suggests that dietary fatty acids 
are a valid option for prevention of obesity associated inflammation in a lean line of pigs, 
regardless of its effects on adiponectin.  With further investigation, it appears that 
alteration of adiponectin concentrations through dietary or pharmaceutical means may be 
a promising treatment for prevention of obesity-related complications.  
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